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Abstract: 
 
Vitamin D, a cumulative class of secosteroid compounds plays an important role in the structural 
development of all forms of vertebrates since the dawn of evolution. As human civilization has 
advanced, scientific curiosities have led toward the discovery of the structures and mechanism of 
biological actions of these secosteroid compounds in the living system, which has revealed that 
this vitamin does not only come from dietary sources rather can be self-produced in the 
mammalians when the body gets sunlight enough, unlike other vitamins. Interestingly it is found 
that this sunshine vitamin is structurally and functionally similar to the steroid hormones, and 
precisely termed as a prohormone. Vitamin D3’s primary metabolite 1a,25-dihydroxyvitamin D3, 
is known to be a major calciotropic hormone, which forms its endocrine system with liver, kidney, 
PTH gland, and more than thirty-six other VDR binding genes present elsewhere in the body to 
regulate the calcium and phosphorus homeostasis. With the increasing urge to unveil the 
importance of 1a,25-dyhydroxyvitamin D3, it has been revealed that this hormone imparts 
substantial antiproliferative and immunoregulatory activities. These findings have directed the 
chemists and biologists to design analogues of vitamin D3, which could furnish a particular 
biological activity over the other, to generate a clinically relevant drug without severe side effects. 
The problem is posed by side effects like hypercalcemia and hypercalciuria when 1a,25-
dihydroxyvitamin D3 is used as an antiproliferative drug. We know that 19-norvitamin D3 can 
significantly reduce those side effects to manifest its antiproliferative activities predominantly. 
Moreover, alteration of A-ring hydroxy group’s geometry can cause a significant change in this 
hormone’s biopotency. Hence, in this study we have accomplished the synthesis of 1,3-cis-25-
dihydroxy-19-norvitamin D3 and its 24-difluoro derivatives (24,24-difluoro-1,3-cis-25-dihydroxy-
19-norvitamin D3), to investigate their VDR binding ability. The modified hydroxy group’s 
stereochemistry and substitution at the side chain have exerted different structure-activity 
relationship than that of parent hormone, which have been discussed herein. 
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Chapter 1: Introduction: 
 
Vitamin D is the typical representation of a class of secosteroid compounds, namely Vitamin D2, 
Vitamin D3, etc. Vitamin D had started its journey long back, at the dawn of the evolution.  The 
significant presence of vitamin D can be traced back in the primitive mammalians, such as 
lampreys. Most of the times big ocean fishes, from the lamprey category, are considered to be 
primary dietary source of vitamin D. Although such bony sea animals contain high concentration 
of vitamin D in their body, the vitamin D endocrine system with its full sets of genes and nuclear 
receptors can only be found from the amphibian onwards. This is because these secosteroid 
compounds have started their journey as a biologically inactive side product of the photochemical 
reaction in the ancient life forms. Once living body left the water and landed on the much calcium 
deficient environment on solid ground, absorption of dietary calcium at the intestine became 
necessary to maintain their skeletal health, since then vitamin D started to play its role as a 
calciotropic hormone. Hence, although vitamin D is termed as a vitamin, in reality, it is a primary 
steroid hormone in mammalians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structures of vitamin D3 (1) and its active hormonal form (2). 
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a) Background: 
  
The deficiency of vitamin D can hinder calcium and phosphorus homeostasis in our body 
resulting weak, fragile bones in children as well as in adults, causing various skletal disorders. 
Among which one of the deadliest disease being rickets. The presence of rickets in bony animals 
can even be found in many fossils. The first scientific identification of rickets was made at 1650, 
and since then for almost more than 200 years’ rickets used to be treated with kitchen medicine 
such as olive oil, cod liver oil, or with exposure to fresh air and sunlight. During the scientific 
renaissance of the 20th century, scientists became particularly interested in having an insight into 
the causes behind rickets and to invent its treatment. At that time, the concept was introduced that 
micronutrients from the food play an essential role in maintaining a healthy body. Hence, such 
kind of vital micronutrients were named as vitamin by Funk et. al.1 Soon after that at 1916 
McCollum and Davis et. al. had proved that micronutrients present in the butterfat portion of food 
can treat a rachitic body.2 After a wrong assumption by Mellanby et. al. at 1919, that fat soluble 
vitamin A can treat rickets,3 finally McCollum et. al. discovered at 1922 the existence of a new 
vitamin, namely vitamin D, which was found to be the active ingredient to treat rickets.4 At the 
same time Chick et. al. had shown that sunlight and UV-B light can treat rickets.5 With these two 
findings, finally at 1924 Steenbock et. al. had shown that sunlight or UV-B can convert provitamin 
D to vitamin D in our body.6 At the next the stage was open for the identification and structural 
elucidation vitamin D class of compounds, which was carried out by Windus et. al., Askew et. al. 
and Waddel et. al.7  Since then till 1965 the vitamin D research was concentrating mostly on the 
biological activities of vitamin D, such as its calcium regulatory properties. It used to be assumed 
that vitamin D have a similar mode of action as of other steroid and parathyroid hormones. The 
year 1971 was very crucial in the history of vitamin D, as in this year 1a,25-dihydroxyvitamin D3 
(2) was finally identified as the hormonally active form of vitamin D.11,12 
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Figure 2:  Metabolism of vitamin D3 in human. 
 
 
b)?Metabolism of vitamin D3: 
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(OH)2-vitamin D3. 1a,25-(OH)2-vitamin D3, being the active hormonal form of vitamin D,12 
subsequently, binds to the DBP and has been carried to the nucleus of the cell where it binds to the 
vitamin D receptors (VDR) to generate various genomic responses including calcium and 
phosphorus homeostasis, immune regulatory activities, muscle contraction functions, 
antiproliferative activities, and cardiovascular metabolism related activities (Figure 2).13 
 
 
c) Structural features of vitamin D3: 
 
To date there is no report of single crystal structure of 1a,25-(OH)2D3 (2) itself, but fortunately 
successful X-ray crystallographic results have been reported for vitamin D analogues14, vitamin 
D215 and its derivatives16, vitamin D317 and 25-(OH)-vitamin D318 and for analogues of 1a,25-
dihydroxyvitamin D319 (2) itself. Hence, the structure of 1a,25-dihydroxyvitamin D3 (2) has been 
deduced based on solid state atom display of these crystals and NMR studies at the solution state20b 
as described here. Vitamin D, being a secosteroid has a very flexible structure. The broken B ring 
frees the A ring from the steroid ring rigidity, hence allowing it to have various conformational 
orientations. The most stable conformations for the pendant like A ring, draping from the broken 
B ring, are the a and b chair forms, but many strained intermediates like twist boat conformation 
can also be observed when it binds to the VDR pocket. The broken B ring forms a triene unit, 
which is not planar, the D5,6 and D7,8 double bonds are planar whereas D10,19 bond is out of plane 
giving rise to ~55° angel. The most rigid part of this molecule is the CD ring. Subsequently, it 
becomes the anchoring structure for this molecule. The intact existence of this CD ring system is 
very vital for the biological activities of vitamin D3. The most flexible part of this molecular 
structure is the side chain originating from the D-ring, the six rotatable C-C bond can emerge 729 
staggered conformations and these different orientations direct change in the VDR binding pattern 
of the ligand to the VDR pocket (Figure 3).20 
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Figure 3: Conformational orientations of the ligand and free and bound states. 
 
 
 
d) Literature review: 
 
The study related to Vitamin D has an enriched and well contributed history from the perspective 
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In this report as we are concentrating on the synthesis of 19-nor type vitamin D3, we will discuss 
about a few synthetic routes towards 1a,25-dihydroxy-19-norvitamin D3. The synthetic routes can 
be separated mainly into two categories. The first one being the direct synthetic route which uses 
vitamin D3 as a starting material and the second approach is the indirect route where mainly the 
A-ring synthon is made starting from naturally occurring chiral compounds such as D-(-)quinic 
acid or 1,3,5-cyclohexanetriol and finally the D5-6 and D7-8 double bond is formed by different 
olefination reactions. Both methods have their own advantages and disadvantages which can be  
summed up as follows (Table 1). 
 
 
Table 1: Comparison between direct and indirect synthetic routes. 
 
Direct synthesis: 
The first synthesis of 1a,25-dihydroxy-19-norvitamin D3 was performed by DeLuca et. al. at 1990 
which was a direct synthesis (Figure 5).22 They had started their synthesis from vitamin D3 and 
after a few step they had got cyclovitamin 5a, which is the key intermediate for this synthesis. The 
cyclovitamin (5a) was then treated with osmium tetraoxide in pyridine to afford the diol 5b. 
Compound 5b was treated with saturated sodium peroxide to give the ketone 5c which was then  
     Synthetic 
    Approach 
                  Advantages                 Disadvantages 
Direct  
synthesis 
1) Less Number of steps. 
2) Stereochemistry of the 
target compound can  
easily be controlled. 
3) Issues of C1 and C25 
hydroxylation  
can be addressed more 
efficiently.  
1) Not versatile for 
derivatization.  
2) As a starting material  
instability of  
vitamin D3 is an added 
inconvenience. 
Indirect 
synthesis 
1) Very useful for structural 
derivatization. 
2) Chiral pool synthesis allows 
more flexibility to change  
stereochemistry easily if 
desired. 
3) Reduced cost of synthesis. 
4) More robust conditions can 
be applied. 
1) Many steps are required. 
2) Encounters severe 
problem 
during installation of  
C25 hydroxy group. 
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Figure 4: Synthetic routes to vitamin D3 and its analogues. 
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Figure 5: Direct synthesis of 19-norvitamin D3 by DeLuca et. al. 
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synthesize both 19-norvitamin D3 and D2. The key synthetic feature of their synthesis can be 
discussed as follows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Direct synthesis of 19-norvitamin D3 by Nagasawa et. al. 
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In this synthesis the procedure up to ketone 6c is similar as what reported by DeLuca et. al. Using 
the ketone 6c they have tried the C1 hydroxylation at the first place, because C1 and C25 
hydroxylation at the vitamin D system always demand special attention. Their first approach was  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Indirect synthesis of 19-norvitamin D3 by DeLuca et. al. 
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failed which used a Rubottom oxidation, reduction and deoxygenation sequence. Later they have 
converted ketone 6c to 6d which is a triflate, and then the triflate was subjected to a 
hydroformylation reaction to give compound 6e. A 9-BBN reduction on compound 6e could 
successfully install the C1 hydroxy group. Later cycloreversion by acetic acid and deprotection of 
the MOM group using camphosulfonic acid had successfully afforded 19-nor vitamin D3. 
 
 
Indirect synthesis: 
 
DeLuca et. al. had reported the first indirect synthesis of 19-norvitamin D3 in 1991 (Figure 7).24 
They have started the synthesis from the naturally occurring D-(-)-quinic acid. As mentioned 
previously being an indirect method this method required many steps. First the carboxylic acid 
was protected as an ester and the C3 and C5 hydroxy groups were protected using TBSCl (7a). 
The C4 hydroxy group was deoxygenated using a two step Barton McCombie deoxygenation 
sequence to give compound 7c, a a-hydroxy group assisted reduction on which gave the diol 7d. 
The diol was then undergone an oxidative cleavage using sodium periodate to give ketone 7e which 
was then subjected to a Peterson olefination reaction to get the E-olefin. The a,b-unsaturated ester 
7f was reduced by DIBAL-H to give allylic alcohol 7g. The alcohol was then converted to an 
allylic chloride 7h, which was then phosphorylated using diphenyl phosphine and n-BuLi in THF 
and oxidized using 30% H2O2 to get the A-ring synthon 7i. That A-ring synthon was reacted with 
the C,D ring synthon, which was a protected Grundmann’s ketone to construct the D7,8 double 
bond of the 19-nor vitamin D3, using a Horner-Witting coupling with n-BuLi. This particular 
reaction is limited by some disadvantages such as: 
• A huge excess of phosphine oxide (A-ring synthon) is required. 
• Give excellent yield only in 80-100 mg or larger scale. 
• In smaller scale the yield is very poor. 
• Very low reaction temperature (-78 °C) is required, at that temperature it is virtually 
impossible to eliminate water contamination completely in a very small scale reaction. 
These technical problems in a very small scale reaction were addressed by Takahasi et. al.25 in the 
year 2006. They have developed an alternative condition for the Horner-Wittig olefination. In their 
condition they have treated a mixture of phosphine oxide and Grundmann’s ketone in nearly 
stoichiometric ratio in THF ant -20 °C with Lithium hexamethyldisilazide (LiHMDS) and the 
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temperature was gradually raised up to 50 °C. This method provides an excellent yield for a small 
scale synthesis (~10 mg). After the coupling reactions the hydroxy protections were removed to 
produce the desired ligand (1a,25-dihydroxy-19-norvitamin D3). 
 
In 1995 Vandewalle et.al. have reported another indirect approach starting from D-(-)-quinic acid 
(Figure 8).26 In this strategy they have first tried the removal of C1 and C4 hydroxy groups, to do 
so they have taken the advantage of lactone 8a, then they have tried to protect the C3 hydroxy 
group selectively by exploiting the equatorial disposition of that hydroxy group. But in practice a 
4:1 ratio of equatorial vs axial alcohols were obtained (8b) which was separated by preparative 
column chromatography. Compound 8b was subjected to a two steps Barton McCombie 
deoxygenation sequence to give compound 8c. Compound 8c was converted to an ester enolate 
(8d) which was then used at the key step to give the bicyclic compound 8e. The ester in compound 
8e was converted to an aldehyde by an oxidation and reduction reaction sequence to give aldehyde 
8f, which was then smoothly converted to the terminal alkyne (8g) via Seyferth’s method using 
dimethyl diazomethylphosphonate. The reaction of 8g and a protected Grundmann’s ketone gave 
the propargylic alcohol which was reduced with lithium aluminium hydride to give the E-allylic 
alcohol, 8h.  An acid catalyzed solvolysis followed by removal of protecting groups had afforded 
1a,25-dihydroxy-19-norvitamin D3. 
 
Recently Nagasawa et. al. has reported another indirect synthetic route to synthesis 19-nor vitamin 
D3 starting from an acyclic starting material (Figure 9).27 The synthesis was started from an acyclic 
epoxy alcohol derivative (9a) which was made from 1,3-propanediol via Sharpless asymmetric 
epoxidation reaction.  Iodination of the primary alcohol by iodine and triphenyl phosphine and 
imidazole followed by treatment with activated zinc and protection of free hydroxy group gave the 
allylic alcohol 9b. Alcohol, 9b was then subjected to a Swern oxidation reaction, to afford the 
aldehyde 9c. Then a Reformatsky type coupling reaction between 9c and Ethyl-2-
(bromoethyl)acrylate gave 9d as a 3:2 diastereomeric mixture. Compound 9d was first oxidized 
and the protecting group was removed, then a hydroxy group assisted reduction gave alcohol 
selectively with desired stereochemistry at C1 position. After that the free hydroxy groups were 
protected again with TBSCl to give compound 9e. Then the a,b-unsaturated ester at 9e was  
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Figure 8: Indirect synthesis of 19-norvitamin D3 by Vandewalle. 
 
 
reduced by DIBAL-H and the resulting hydroxy group was protected with acetate group to get 
compound 9f. The compound 9f was subjected to a ring closing metathesis (RCM) reaction using 
Grubb’s (II) catalyst to afford the cyclic intermediate 9g, which is the key intermediate for this 
synthesis.  
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Figure 9: Indirect synthesis of 19-norvitamin D3 by Nagasawa et. al 
. 
 
9g was then reacted with a C,D ring boronate in the presence of palladium catalyst to give the 
protected 19-nor compound, removal of the protecting group at which could afford 1a,25-
dihydroxy-19-norvitamin D3. 
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e) Conclusion: 
 
In this chapter a small history of vitamin D chemistry and biology have been discussed along 
with the solution state conformation of vitamin D3. The metabolic path, following which vitamin 
D3 is synthesized in our body starting from 7-dehydrocholesterol in presence of sunlight is 
discussed to provide a better understanding about the exclusiveness of vitamin D than the other 
vitamins. A brief literature review at the end of this chapter have ensured a better understanding 
about the chemistry related to the 19-norvitamin D3 and have pioneered a path towards our 
investigation related to 1,3-cis-19-norvitamin D3 derivatives in this study thereafter. 
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Chapter 2: Synthesis of 1,3-cis-1a,25-(OH)2-19-norvitamin D3: 
 
 
a) Target compounds in this study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Structures of 5a and 5b 
 
In this chapter we will discuss the synthesis of two analogues of 19-norvitamin D3 namely 
1b,3b,25-dihydroxy-19-norvitamin D3 (5a) and 1a,3a,25-dihydroxy-19-norvitamin D3 (5b) 
(Figure 10). 
 
b) Motivation: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Structure of active hormone 2 and its isomers 2a and 3. 
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1a,25-Dihydroxyvitamin D3 (2, Figure 11; also known as calcitriol), which is the hormonally 
active form of vitamin D3 in mammalians, regulates calcium and phosphorus homeostasis,28 and 
also has antiproliferative, cell differentiation-inducing, and immune-regulatory activities.29 It is 
used to treat hyperproliferative disorders, but its clinical utility is limited by side effects such as 
hypercalcemia and hypercalciuria, which are induced at clinically effective doses.  Hence, there is 
a need for structural modification to separate these biological activities.30 Aiming at that purpose 
modifications at the A-ring look promising as that can change the orientation of the hydroxy groups 
inside the VDR pocket changing the geometry of ligand-receptor complex, generating different 
type of biological responses than that of parent hormone. When C1 of the parent hormone is 
epimerized to give1b,25-dihydroxyvitamin D3 (2a), compound 2a does not show any calcemic 
activity even when used in a 1000-fold excess than that of natural hormone.31 On the other hand 
1a,25-dihydroxy-19-norvitamin D3 has a characteristic biological activity profile, exhibiting high 
differentiation potency towards various malignant tissues with a greatly reduced calcemic 
effect.32c-d 
Hence, in our attempt to design vitamin D analogues to exhibit selective structure-activity 
relationship profile, we have decided to merge the structural features of compound 2a and 3. 
Therefore, in our synthetic target we have trimmed of the 19-exomethylene group and have 
epimerized C1 and C3 respectively to get compound 5a and 5b.  
 
c) Retrosynthesis of target compound: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1:    Retrosynthetic strategy for 1,3-cis-25-dihydroxy-19-norvitamin D3 (5a and 5b) 
employing Julia-Kocienski olefination. 
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d) Synthesis: 
 
• Synthesis of the C,D ring synthon: 
 Synthesis of the C,D ring synthon has been carried out as depicted in figure 6 following 
the previously reported methods.32 We have performed the synthesis starting from the 
Grundmann’s ketone 12a (figure 12) and protected the C25 hydroxy with MOM group or TES 
group, respectively  as required for synthesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Synthesis of the C,D ring synthon. 
 
The Grundmann’s ketone was prepared from vitamin D3 after ozonolysis and C25 hydroxylation 
as reported in literature.32f Compound 12b was then subjected to a Horner-Wittig olefination 
reaction to give the a,b-unsaturated ester with E-geometry (12c), this ester was further reduced to 
an allylic alcohol 12d, using DIBAL-H in Toluene. The allylic alcohol was subjected to a 
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Mitsunobu reaction followed by ammonium molybdate tetrahydrate catalyzed oxidation to 
produce our desired sulfone, which is the C,D ring synthon for the synthesis of our desired target 
compounds. 
 
• Synthesis of the A ring synthon: 
Synthesis of ketone 7 is illustrated in scheme 2.  1,3,5-Cyclohexanetriol (8) was reacted with 
phenylboronic acid in toluene under reflux condition to give the boronate, whose free hydroxy 
group was then protected as benzoate ester by reaction with benzoyl chloride in the presence of 
triethylamine, affording 9 in 76% yield (2 steps)33, this route is a much efficient and inexpensive 
route to synthesize our target compound than reacting 1,3,5-cyclohexanetriol with phenyl 
orthobenzoate to form an orthoester at the first step.34 The boronate ester in 9 was hydrolyzed 
using pinacol in the presence of BF3·Et2O, and the free hydroxy groups were protected as TBS 
ether using TBS chloride in the presence of triethylamine and tetrabutylammonium bromide 
(TBAB), affording 10 in 52% yield.  After hydrolysis of benzoyl group in 10 with sodium 
hydroxide in methanol, the resulting hydroxy group was oxidized with PCC to give ketone 7 in 
56% yield.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2:   Synthesis of A-ring synthon 7. 
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With ketone 7 in hand, the CD ring synthon 27 (Figure 12) and ketone 7 were coupled using 
LiHMDS in THF35 to give 12 in 98% yield as a 1:1 mixture of diastereomers 12a and 12b (Scheme 
3).  However, separation of these two diastereomers were difficult. Moreover, the chemical shifts 
of 1H at C1 and C3 of these two isomers 12a and 12b overlapped (d 3.6-3.9 ppm), and structural 
identification of these isomers was problematic.  Therefore, we decided to modify the hydroxy 
protecting groups at the A-ring in order to obtain products with different polarity, which would be 
more easily separable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3:   Julia-Kocienski coupling of compounds 7 and 27. 
 
Specifically, we planned to change one silyl ether to benzoate ester in ketone 7 to obtain 
26.  The strongly electron-withdrawing nature of the benzoyl group would make the adjacent C1-
H more deshielded than its C3 counterpart, which should enable facile identification of both H’s 
in 1H NMR.  This group was also expected to induce some polarity difference between the two 
target compounds, enabling us to separate them easily on a preparative scale.  Thus, we attempted 
selective deprotection of one TBS group in 7 using TBAF (1 eq) or HF·Py (1 eq). However, b-
elimination and subsequent aromatization reaction took place to generate 14 and 15, respectively 
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(Scheme 4).   These results led us to develop a new route to synthesize an A-ring synthon with 
different hydroxy protecting groups at the C1 and C3 positions (26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4:   Attempt to synthesize 26 from 7. 
 
 
 
• Synthesis of 26: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5: Synthesis of diol 20 from D-(-)-quinic acid. 
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We have started our synthesis of 26 from D-(-)-quinic acid (16), which was methylated using 
SO2Cl2 in methanol, and then two hydroxy groups were protected using TBSCl in DMF in 
conjugation with DMAP and Et3N, to give compound 17. The secondary hydroxy group at 17, was 
reacted with TCDI in CH2Cl2 to give compound 18, which was deoxygenated using AIBN and 
NaH2PO2.xH2O in 2-methoxymethanol to yield 19 in 70% yield. Ester 19 was reduced by sodium 
borohydride in ethanol to give diol 20 (Scheme 5).32a,22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6:   Synthesis of 1,3-cis alcohol 24 
 
The diol 20 was protected with benzaldehyde dimethylacetal to give acetal 21 in 82% yield.  
We found that selective deprotection of one TBS group in 21 proceeded upon slow addition of 
TBAF in THF (1 M in THF, 1 eq) at 0 °C to give a mixture of four stereoisomers 22 in 70% yield.  
This mixture of isomers was oxidized with TPAP-NMO to give ketone 23 (mixture of four 
isomers).  Various conditions were investigated for the stereoselective reduction of ketone 23 to 
1,3-cis alcohol 24.  Among them, DIBAL-H in the presence of ZnCl236 was effective, and 1,3-cis 
alcohol 24 (more polar) was obtained in 67% yield, together with 1,3-trans alcohol 22 (less polar, 
29%) after silica gel column separation (Scheme 6). 
 
OH
OTBSTBSO
1M TBAF
70% (brsm)
PhCH(OMe)2
PPTS
20
82%
HO O
O Ph
TBSO OTBS
21
O
O Ph
TBSO OH
22
(4 isomers)
TPAP
NMO
O
O Ph
TBSO O
23
(4 isomers)
DIBAL-H
ZnCl2
O
O Ph
TBSO OH
24
(4 isomers)
+ 22
	 25	
 
 
 
 
 
 
 
 
 
 
Scheme 7: Synthesis of A-ring synthon 26 
 
After protection of the hydroxy group in 24 as benzoate by reaction with benzoyl chloride and 
DMAP (25), deprotection of benzelidene acetal under hydrogenolysis conditions in the presence 
of palladium hydroxide followed by oxidative cleavage of the resulting diol with NaIO4 aqueous 
solution in methanol afforded ketone 26.   
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e) Reduction conditions: 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Borohydride reduction conditions to obtain cis alcohol 24. 
 
First we have tried a series of borohydride reduction conditions on ketone 23 to optimize the 
condition for getting cis alcohol 24 (Table 2). Sodium borohydride or lithium borohydride gave 
major trans product, whereas bulky reagent like L-Selectride showed complete trans selectivity. 
Other reduction conditions such as zinc borohydride, lithium aluminium hydride or borane could 
yield 1:1 mixture of cis:trans alcohol, but none of this conditions could afford a majority of desired 
Reducing 
   Agent Solvent
Temperature
      (oC)
23   22trans
 24
 cis
NaBH4                  EtOH                   0                          -                      2                      1          92
 NaBH4                  EtOH                 -40                         -                      2                      1          92
 LiBH4                    EtOH                   0                          -                      2                     0.7        90
Zn(BH4)2                THF                    0                          -                      1                      1          70
Me4NBH4               THF                    0                    decomp.                -                       -           -
L-Selectride           THF                 -20                         -                       1                      -           99
L-Selectride           THF                 -40                         -                       1                      -           99
 LiALH4                  THF                 -78                         -                       1                      1          85
BH3·THF                 THF                   0                          -                       1                      1         99
Table 1 : Borohydride Reductions
O
OTBSO
O
Ph
23
Reduction 
conditions
O
TBSO
O
Ph
O
TBSO
O
Ph
OH OH
22 24
+
yield
 (%)
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cis product. Therefore, we have decided to extend the scope of this reduction reaction employing 
Lewis acid promoted hydride reductions as shown in Table 3 and 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Lewis acid promoted hydride reductions of ketone 23. 
 
When borane trichloride (BCl3) was used as a Lewis acid in conjugation with sodium 
borohydride, BH3·SMe2, or sodium cyanoborohydride complete decomposition of ketone 23 was 
observed, due to elevated acidic environment into the reaction vessel. Similar results were found 
when DIBAL-H was used in conjugation with TiCL4 or ZrCl4 (Table 3). 
 
 
 
O
OTBSO
O
Ph
23
Reduction 
conditions
O
TBSO
O
Ph
O
TBSO
O
Ph
OH OH
22 24
+
Reducing
   agent Lewis acid Solvent 23
  22
trans
 24
 cis
  NaBH4             BCl3             THF                0           -             2              1        66
Temp.
 (oC)
NaBH3CN         BCl3            CH2Cl2           -78    decomp.      -               -         -
BH3.SMe2         BCl3            CH2Cl2           -78    decomp.      -               -         -
BH3.THF          BCl3            CH2Cl2           -78    decomp.      -               -         -
 DIBAL-H          TiCl4            CH2Cl2           -78    decomp.      -               -        -
DIBAL_H          ZrCl4           CH2Cl2           -78    decomp.     -                -        -
yield
  (%)
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Table 4: Lewis acid promoted reductions of ketone 23. 
 
However, significant positive change was found when milder Lewis acid such as nickel 
bromide (NiBr2), copper chloride (CuCl2) or zinc chloride (ZnCl2) were used with DIBAL-H 
(Table 4). In each case almost 2:1 cis:trans ratio were found, but considering the overall yields, 
and inexpensiveness of reagents ZnCl2/DIBAL-H couple in CH2Cl2 at -78 °C stood out as the best 
reduction condition. To our satisfaction, all four isomers of the ketone 23 showed quite similar 
result when our optimized condition was employed on them to get the cis alcohol. 
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O
Ph
23
Reduction 
conditions
O
TBSO
O
Ph
O
TBSO
O
Ph
OH OH
22 24
+
Reducing 
   agent Lewis acid Solvent
Temp
 (oC) 23
  22
trans
 24
 cis
 DIBAL-H          NiBr2         CH2Cl2         -78            -             1         1.8       88
  DIBAL-H          CuCl2         CH2Cl2         -78            -             1         2.0       85
DIBAL-H          SnCl2         CH2Cl2         -78      decomp.       -           -          -
DIBAL-H          ZnCl2         Toluene        -78             -             1        0.6       56
DIBAL-H          ZnCl2            THF           -78             -             1        2.0       78
DIBAL-H         ZnCl2         CH2Cl2         -78             -              1        2.3       96
yield
 (%)
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f) Synthesis of 5a and 5b: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8: Synthesis of 5a and 5b. 
 
Coupling reaction of CD-ring synthon 27 with ketone 26 was performed to give 28a and 28b.  
These two diastereomers were separable by silica gel column chromatography, affording 28a and 
28b in 36% and 35% yield, respectively.  The structures of these isomers were confirmed by 1H 
NMR and NOESY (Figure 13).37 These isomers were converted to 1,3-cis-19-nor vitamin D3 5a 
and 5b in 56% and 59% yield, respectively, by reaction with potassium carbonate in methanol-
THF followed by deprotection of silyl ethers with HF·Py (Scheme 8). 
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g) Structural elucidation of diastereomers: 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Coupling constant and NOE correlations in 28a and 28b 
 
 
 
For both compound 28a and 28b preferred conformations have been shown (Figure 13), which is 
also supported by the 2JHH values. The high coupling constant values (Table 5) confirm the axial 
disposition of C1 and C3 Hs in each case. In case of 28a, series of NOE correlations have been 
found among H3a-H4a, H4a-H6 and H6-H9b which proves the 1b,3b geometry of the protected 
hydroxy groups at 28a. Similarly, in case of compound 28b, NOE correlations among H4a-H6 and 
H6-H9b (Table 5) have been observed, concluding a 1a,3a geometry for the A ring of 28b. 
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Table 5: Coupling constants for C1 and C3 proton of 28a and 28b 
 
 
h) Conclusion: 
 
A new route to synthesis 1,3-cis-19-notvitamin D3 derivatives has been developed. This route is 
inexpensive and is very versatile to afford huge number of 1 and 3 modified derivatives of vitamin 
D3 by simply changing the substituent at the A-ring synthon. Using this route, we have synthesized 
both 1a,3a (5b) and 1b,3b (5a) derivatives at the same time. The hindrance at diastereomer 
separation has successfully been overcome by modifying the A-ring synthon. Finally, 1a,3a,25-
dihydroxy-19-norvitamin D3 and 1b,3b,25-dihydroxy-19-norvitamin D3 have been synthesized 
and their structures were elucidated using 1D and 2D spectroscopy. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound H-H J (Hz) NOE (H-H) 
28a 3a-4b 13.0 3a-4a 
1a-10b 12.8 4a-6 
   6-9b 
28b 3b-4a 12.4 4a-6 
1b-10a 10.9 6-9b 
  10b-7 
  1b-3b 
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Chapter 3: Synthesis of 24,24-difluoro-1,3-cis-1a,25-(OH)2-19-   
norvitamin D3. 
 
a) Synthetic target: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Structure of 6a and 6b. 
 
 
In order to extend our study concentrating on the cis-19-norvitamin D3, in this work, we have 
decided to synthesis two 24-difluoro derivatives, 24,24-difluoro-1b,3b,25-dihydroxy-19-
norvitamin D3 (6a) and 24,24-difluoro-1a,3a,25-dihydroxy-19-norvitamin D3 (6b) (Figure 14). 
 
 
 
b) Motivation for synthesis: 
 
25-Hydroxyvitamin D3 is metabolized in the liver and kidney under enzyme cytochrome P450, 
named CYP24A1. At kidney, first it gets oxidized at the C1 position to produce the active 
hormonal form, but the oxidation does not stop there. The side chain carbons such as C24 or C26 
are very prone to undergo such cytochrome oxidation. 24R,1a,25-(OH)3-vitamin D3 (Figure 15) 
is a very unstable metabolite and it is easily catabolized further under oxidative environment to 
side chain truncated, water soluble, biologically inactive end products, such as calcitroic acid 
(Figure 15).38 A detail description of other catabolites of 1a,25-dihydroxyvitamin D3 under 
CYP24A1 path is shown in figure 16. Hence, it is evident that, CYP450 oxidations shorten the  
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Figure 15: CYP24A1 oxidation path of 25-(OH)-VD3, showing resulting metabolites. 
 
 
metabolic stability of the ligand inside the body and to enhance its metabolic stability it is 
important to inhibit such oxidations. One way to inhibit such oxidations is to replace the 
hydrogen(s) at the oxidation sites with fluorine. The small size of fluorine allows effective overlap 
of 2s and 2p orbital to the corresponding orbital of carbon, moreover high electronegativity of 
fluorine always causes the C-F bond to be significantly polarized in nature which can inhibit the 
oxidation by CYP24A1 and enhances metabolic stability.39 Indeed, 24,24-difluorinated 1a,25-
dihydroxyvitamin D3 showed higher metabolic stability and almost 100% absorption in rats, 
although this enhanced metabolic stability did not yield increased biological activity.40 On  the 
contrary 24,24-difluoro-1a,25-dihydroxy-19-norvitamin D3 (4, Figure 17) promotes bone 
formation more effectively, and shown stronger VDR binding than not only its non-fluorinated 
derivatives, but also than the natural hormone.41 These observations indicate to the fact that C24 
substitution can significantly increase biological activities in case of 19-nor type vitamin D3, 
beside enhancing its metabolic stability. 
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Figure 16: Catabolites of 1a,25-dihydroxyitamin D3 under cytochrome oxidation. 
H
OH
HO OH
1a,25-Dihydroxyvitamin D3
23
-Hy
dro
xy
lat
ion
 pa
th.
23
24
26
25
26-Hydroxylation Path.24-hydroxylation          path.
OHOH
1,23S,25-(OH)3D3
OHOH
1,23S,25,26-(OH)4D3
OH
OHO OH
1,25R-(OH)2-23S,26-lactol D3
OHO O
1,25R-(OH)2-23S,26-lactone D3
OH
1,24R,25-(OH)3D3
OH
OH
1,25-(OH)2-24-oxo-D3
O
OH
1,23S,25-(OH)3-24-oxoD3
O
OH
OH
1,23-(OH)2-tetranorD3
CHO
Calcitral
Calcitroic acid
OH
O
OH
1,25S,26-(OH)3D3
OH
	 35	
Hence, we have decided to extend our study of 1,3-cis-25-dihydroxy-19-nor-vitamin D3 
derivatives to its 24-difluorinated series, to synthesis 6a and 6b (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Structure of active hormone 1 and its 19-nor form 3 and 4 
 
 
 
c) Synthesis: 
 
Here we have adopted similar methodology, employing a Julia-Kocienski olefination like 
previous, using ketone 26 and sulfone 38, to get both isomer 6a and 6b at the same time.  The 
sulfone 38 was synthesized from Grundmann’s ketone 35, which was reported by DeLuca and co-
workers41a (Scheme 9). We have started the synthesis of compound 35 from Vitamin D2, which 
was subjected to an ozonolysis reaction at -78 °C in methanol by bubbling O3 gas followed by 
addition of sodium borohydride to give the much known compound Inhoffen Lythgoe diol. The 
primary alcohol of the diol was then protected with tosylate group using tosyl chloride (TsCl) in 
Pyridine, and the secondary hydroxy group was protected using TESOTf and 2,6-lutidine in 
CH2Cl2 at 0 °C to give compound 29 in 85% overall yield. The compound 29 was then subjected 
to a cynation reaction using sodium cyanide (NaCN) in DMSO at 90 °C followed by DIBAL-H 
reducation in CH2Cl2 at -78 °C to produce aldehyde 30. A Reformatsky coupling reaction was 
performed on the aldehyde (30) to introduce the fluorinated side chain. Compound 30 was treated 
with bromodifluoro ethylacetate (BrF2CCO2Et) in presence of Zn dust in THF under reflux 
condition to give compound 31 as a 1:1 diastereomeric mixture in 69% yield. The free hydroxy 
group of compound 31 was removed by a Barton McCombie deoxygenation process. The hydroxy 
compound (31) was treated with 1.1’-thiocarbonylimidazole in THF, and then was reacted with  
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Scheme 9: Synthesis of Grundmann’s ketone 35. 
 
triethylsilane (Et3SiH) in Toluene using benzoyl peroxide as the radical source under reflux 
condition to give deoxygenated difluoroester 33 in 92% yield. The ester 33 was the subjected to a 
Grignard reaction using 2 eq. of methyl magnesium iodide (MeMgI) to introduce the C25 hydroxy 
group (34). After this the TES group of compound 34 was removed using TBAF in THF and the 
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free secondary hydroxy group was oxidized by TPAP-NMO in CH2Cl2 at 0 °C to get the 
Grundmann’s ketone derivative. The C25 hydroxy group was the protected using TMS-I in CH2Cl2 
to give compound 35 in overall 81% yield (3 steps) (Scheme 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10:   Synthesis of sulfone 38 
 
Compound 35 was subjected to Horner-Wittig olefination using triethyl phosphanoacetate in the 
presence of sodium hydride in THF to give a,b-unsaturated ester 36, and the ester was then 
reduced with DIBAL-H in toluene to give the allylic alcohol 37 in 68% yield (2 steps).  The allylic 
alcohol 37 was subjected to Mitsunobu reaction using 2-mercaptobenzothiazole in the presence of 
diisopropyl azodicarboxylate (DIAD) and triphenyl phosphine in CH2Cl2, followed by hydrogen 
peroxide oxidation of the resulting sulfide in the presence of ammonium molybdate tetrahydrate 
catalyst32d to give sulfone 38 (Scheme 10). 
With sulfone 38 and ketone 26 (Scheme 7) in hand, we performed Julia-Kocienski coupling to 
obtain a mixture of 39a and 39b, which was separated by silica gel column chromatography. The 
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relative stereochemistries were assigned on the basis of 1H NMR and NOE correlations, as reported 
previously.37 Each compound was subjected to two-step deprotection using K2CO3 in methanol, 
followed by HF·Py in THF, to afford 6a and 6b, respectively, in 64% yield (Scheme 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11:  Synthesis of 6a and 6b. 
 
d) Conclusion: 
 
24,24-Difluoro-1a,3a,25-dihydroxy-19-norvitamin D3 and 24,24-difluoro-1b,3b,25-
dihydroxy-19-norvitamin D3 have been synthesized and separated using our strategy developed at 
chapter 2, which proves the practical implementation of our strategy to synthesis 1,3-cis-19-
norvitamin D3 derivatives. 
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Chapter 4: VDR binding affinities of synthesized analogues. 
 
a) Introduction: 
 
In 1974 Brumbaugh and Haussler42 and Lawson and Wilson43 discovered the presence of a 
protein macromolecule in the chromatin fraction of the chick intestine that can mediate preferential 
nuclear uptake of vitamin D, and it was detected as vitamin D receptor (VDR). Later in 1975 
Brumbaugh and Haussler44 have shown that VDR is specifically capable of binding to 1a,25-
dihydroxyvitamin D3 with very high affinity. It was also reported that this vitamin D receptor’s 
characteristic are quite similar to that of nuclear receptor.45 The human VDR is denoted as VDR 
gene. The presence of VDR was primarily traced largely in chicken intestine along with other 
organs like kidney, bone ad parathyroid gland cells in mammalians, which was proved to regulate 
calcium and phosphorus homeostasis in the body.46 Later with considerable increase in findings 
about the biological role (especially the cellular proliferation and differentiation) of 1a,25-
dihydroxyvitamin D3, vitamin D receptor (VDR) was traced in many other organs such as 
pituitary47, placenta48, ovary49, testis50, and heart51. 
 
Nuclear receptors are a class of protein that can bind specifically to steroid and thyroid hormones. 
There are two types of nuclear receptors that is class I nuclear receptor and class II nuclear receptor. 
VDR is also known as calcitriol receptor and NR1I1 receptor, that is nuclear receptor of subfamily 
1, group I, and member 1. The structure of VDR is quite similar to that of the nuclear receptors, 
which can be separated into five domains (Figure 18), which are described below: 
 
 
 
 
 
 
 
 
 
 
Figure 18: Five regions of a nuclear receptor. 
 
A/B C D E F
DNA binding
    domain.
Ligand binding domain.
N-terminal
  domain.
C-terminal
  domain.
 Hinge
region.
	 40	
• A/B region: This is known as the N-terminal domain and it contains the activation function 
1 (AF-1). The action of this part is independent of the ligand. The action of AF-1 combines 
with AF-2 to cause gene expression in the E-domain. 
• C region: This region is known as the DNA Binding Domain or the DBD. The two zinc 
fingers present in this region specifically binds to the sequence of DNA called hormone 
response elements (HRE). 
• D region: This region is known as the hinge region. This portion of the nuclear receptor 
connects the DNA binding domain (DBD) to the ligand binding domain (LBD). 
• E region: This region is known as the Ligand Binding Domain or the LBD. The structure 
of this domain when binds to the vitamin D ligand is discussed in details in the following 
paragraph. 
• F region: This portion of the nuclear receptor is called the C-terminal domain and the 
sequence of this domain varies highly from one nuclear receptor to another. 
 
 
The helices 1 and 3 in case of vitamin D receptor is somewhat elongated than the other nuclear 
receptor which seems to pose a problem during the attempt of crystallization of vitamin D ligand 
and receptor. The first VDR structure for an LBD was reported at 2000 by Rochel et. al.52 where 
they have removed the flexible insertion domain containing fifty amino acid segments from 
between helices H1 and H3 in order to get the crystallized ligand-domain complex. 
The salient features those were revealed about the structure of the ligand inside LBD are noted 
here to understand the structure of the active vitamin D3 in a ligand bound state. 
 
• The size of ligand binding cavity of VDR is 697Å which is larger than many other nuclear 
receptor’s cavities. The ligand occupies only 56% of the total volume of the cavity. 
Additional spaces are allocated near the C2 position of the A-ring which is usually 
occupied by two molecules of water, and near the aliphatic chain on D-ring which may 
allow different length of aliphatic chain to fit inside. 
• The A-ring adopts a b-chair form with the 1-OH and 3-OH in equatorial and axial position 
respectively. 
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• The triene system adopts a curved geometry in the bound state than the planar geometry in 
the free state. 
• The ligand binding pocket is predominantly lined with hydrophobic residue. The ligand 
adopts an elongated shape, where the A-ring touches the helix H3 oriented towards C-
terminal of helix H5 and the C25 hydroxy group close to helices H7 and H11.  
• The A-ring hydroxy groups that is the C1 and C3 –OH groups respectively are separated 
from the C25 –OH groups by 13Å and 15.4Å. 
• The three hydroxy groups forms six H-bonds with the hydrophilic residues, i.e. two 
hydrogen bonds for each hydroxy groups (Figure 19), such as 
§ C-1 hydroxy group with Ser-237 (H3) and Arg 274 (H5). 
§ C-3 hydroxy group with Ser-278 (H5) and Tyr-143 (only conserved in mammals). 
§ C-25 hydroxy group with His-305 (loop H6-H7) and His-397 (H11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Figure 19: Hydrogen bonds in the ligand-domain complex. 
 
 
• The conjugated triene that connects the A and C ring are tightly sandwiched between the 
hydrophobic residues from Ser-275, Trp-286 in one side and Leu-233 on the other side.  
• The C6-C7 single bond exhibits a trans conformation that deviates by 30° from planarity. 
• The aliphatic chain at position C17 on D-ring adopts an extended conformation almost 
parallel to C13-C18 bond. 
 
These characteristic features of the active ligand while bound to the the VDR can explain the 
biological activity of the analogues to great extent. 
H
O
OO
Arg-274
H Ser-237
Ser-278
H143-Tyr
His-397
H His-305
	 42	
b) Experimental procedure: 
 
The binding affinity of 1a,25-dihydroxyvitamin D3, 1a,25-dihydroxy-19-norvitamn D3, 24,24-
difluoro-1a,25-dihydroxy-19-norvitamin D3, and their derivatives 5a, 5b, 6a, and 6b for VDR was 
examined using a nuclear receptor cofactor assay system (Enbio RCAS for VDR, EnBioTec 
Laboratory) according to the manufacturer’s instructions.53 First, the kit components were brought 
down at room temperature. The standard was reconstituted with 1.0 mL of standard diluent and 
was kept for 10 mins at room temperature with occasional shaking. The initial concentration of the 
stock solution was 200 ng/mL, which was then diluted to yield seven standard solutions of different 
concentration. The highest concentration of stock solution being 20 ng/mL and the lowest being 
0.312 ng/mL, with one blank solution. The working concentrations were diluted with detection 
reagent A and B respectively (1:100).  
7 wells were determined for standard and 1 well for the blank. 100 µL of each dilution of standard, 
blank and samples were added to appropriate wells. Then those wells were covered with plate 
sealer and was incubated for 2 h at 37 °C. After that liquid was removed from each well, and 100 
µL of working solution with detection reagent A was added to each well and was incubated for 1 
h at 37 °C after covering with plate sealer. Then the wells were washed with 350 µL of Wash 
solution and was allowed to sit for 1-2 mins. Remaining liquids were removed from all wells by 
snapping the plates on absorbent paper. This wash process was repeated for 3 times, and after the 
last wash, any remaining buffer was completely removed by aspirating or decanting the wells. 100 
µL of detection reagent B was added to each well and was incubated for 30 mins at 37 °C after 
covering the plates with plate sealer. The aspiration process was repeated to wash the buffer 
completely for five times. Then 90 µL of substrate solution was added to each well and was 
covered by a new plate sealer, which was then allowed to incubate for 10 mins at 37 °C, the liquid 
was turned blue by the addition of substrate solution. Then 50 µL of stop solution was added to 
each well, the liquid in the wells turned into yellow upon addition of stop solution. The sides of 
the plate were tapped to mix the liquid inside, any drop of water and any trace of fingerprint were 
removed from the bottom of the plates. After that, those plates were immediately replaced under 
microplate reader at 450 nm to conduct the measurements.  
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c) VDR binding assay: results and discussion: 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6:   VDR-binding affinities of compounds 2-4, 5a, 5b, 6a, and 6b.a 
 
 
aThe binding affinity of vitamin D analogues 2-6 for VDR was examined using a nuclear receptor 
cofactor assay system (Enbio RCAS for VDR; EnBioTec Laboratories, Tokyo, Japan) according 
to the manufacturer’s instructions, as described previously.53 
 
 
  The vitamin D receptor (VDR) affinities of the 24-difluoro analogues 6a and 6b and their 
corresponding non-fluorinated derivatives 5a and 5b were evaluated.  Compounds 5a and 5b 
showed very weak binding affinity, with IC50 values of 24.2 µM and 2.1 µM, respectively, 
compared to that of the control compound 19-nor analogue 3 (Table 6, entries 2, 4, and 5).   
However, 24-difluoro substitution markedly increased the VDR-binding affinity.  Compound 6a 
showed almost 400-fold greater binding affinity than that of 5a, while 6b exhibited almost 30-fold 
greater binding affinity than that of its non-fluoro derivative 5b.  However, the binding affinities 
of 6a and 6b are still several orders of magnitude less than those of the native hormone (2) and 
24,24-difluoro-1a,25-(OH)2-19-norvitamin D3 (4), although the binding affinities of compound 
6a and 6b are almost same (Figure 20).  These results suggest that 24-difluoro substitution 
significantly alters the side chain geometry in the VDR pocket in case of 19-norvitamin D3 
analogues. 
Entry Compounds VDR binding (IC50)
1 2 21.7 nM
2 3 838.9 nM
3 4 16.6 nM
4 5a 24.2 µM
5 5b 2.1 µM
6 6a 64.8 nM
7 6b 57.6 nM
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Figure 20: Intensity v/s concentration plot for vitamin D analogs. (D1 = 5b; D2 = 5a; D3 = 1a,25-
dihydoxy-19-norvitamin D3; D4 = 6b; D5 = 6a; D6 = 24,24-difluoro-1a,25-dihydroxy-19-
norvitamin D3). 
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Chapter 5: General conclusion: 
 
 The aim of this study was to develop a synthetic route to synthesize 1,3-cis-19-norvitamin 
D analogues, which has been achieved successfully. Four analogues namely 1b,3b,25-dihydroxy-
19-norvitamin D3 (5a), 1a,3a,25-dihydroxy-19-norvitamin D3 (5b), 24,24-difluoro-1b,3b,25-
dihydroxy-19-norvitamin D3 (6a), and 24,24-difluoro-1a,3a,25-dihydroxy-19-norvitamin D3 (6b) 
were synthesized via a convergent path using the Julia-Kocienski olefination as the key step. 
 
The synthesis of 1,3-cis-19-nor type A-ring synthon from 1,3,5-cyclohexanetriol was 
problematic due to difficulty of separation and identification of the 1,3-cis-19-nor vitamin D3 
isomers 5a and 5b.  A simple strategic modification to protect one hydroxy group with benzoate 
afforded A-ring synthon 19.  Finally, 5a and 5b were synthesized by Julia-Kocienski olefination 
of this A-ring synthon and a CD ring synthon, thus opening up a new route that should be available 
to build a library of 1,3 modified 1,3-cis-19-nor type vitamin D derivatives in a convergent manner.   
To extend the scope of this study another two new 24,24-difluorinated-1,3-cis-25-(OH)2-19-
norvitamin D3 derivatives (6a and 6b) were synthesized using similar methodology.  
 
The VDR-binding affinity of these compounds were measured to understand the effect of 
altered stereochemistry at the C1 and C3 position, and to check the effect of difluoro substitution 
at the C24 position. Compound 5a and 5b showed very poor binding affinity to the VDR pocket. 
The VDR binding of compound 5a with 1b hydroxy group is much less than compound 5b with 
1a hydroxy group, which is in concordance with the previously reported trends in literature. 
Interesting hike in the VDR binding affinity was observed in case of 24-difluoro substituted 
compounds 6a and 6b. Compound 6a had showed 400-fold increase in VDR binding than 
compound 5a and the increase for compound 6b is 30-fold than compound 5b. This result is also 
persistent with previous findings that 24-difluoro substitution in 1a,25-dihydroxy-19-norvitamin 
D3 considerably increase its VDR binding. The most interesting and striking result obtained from 
this study is that, the VDR binding affinity of compound 6a and 6b are almost same (64.8 and 57.6 
nM respectively), although they have different hydroxy group geometry at the C1 position. This 
result implies the fact that the effect of 24-difluoro substitution exerts a positive effect on the 
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binding to the VDR pocket to an extent that can overcome the effect exerted by the C1 hydroxy 
groups geometry. 
The above mentioned results will open a new path to generate a library of 1,3-cis-19-
norvitamin D analogues, which can be tested for their VDR binding affinity and for other 
biological activities.  The positive effect manifested by 24-difluoro substitution will draw the 
attention of chemists and biologists for further study on similar compounds at the molecular level. 
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Chapter 6: 
 
 
Experimental section: 
 
All reactions have been carried out in dry solvents, and under inert atmosphere unless otherwise 
mentioned. Reagents were purchased from Sigma Aldrich, TCI and Wako chemicals. Flush 
chromatography was performed on silica gel 60 (spherical, particle size 40–100 mm; Kanto). 1H 
NMR spectra have been recorded in deuteriochloroform at 300 and 400 MHz using JEOL 
instruments, JMTC 300 and JNM-ECX 400 spectrometers, whereas 13C NMR spectra have been 
recorded at 75 and 100 MHz using the same spectrometers. The spectra are referenced internally 
according to residual solvent signal of CDCl3 (1H NMR: d = 7.26 ppm; 13C NMR: d = 77.0 ppm). 
Data for 1H NMR are recorded as follows: chemical shift (d/ppm), integration, multiplicity (s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad) and coupling constant (Hz). 
Data for 13C NMR are reported in terms of chemical shift (d/ppm). Mass spectra were recorded on 
a JMS-T100X (JEOL) spectrometer in ESI-MS mode using methanol as solvent.  
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(1R,5S)-3-phenyl-2,4-dioxa-3-borabicyclo[3.3.1]nonan-7-yl benzoate (9): 
 
 
 
 
 
 
1,3,5-Cyclohexanetriol, 8 (3.0 g, 22.69 mmol) was dissolved in toluene (250 mL) under argon, and 
the mixture was refluxed for 6 h, when no left over starting material was found at TLC, the reaction 
was cooled to room temperature and the solvent was evaporated under reduced pressure, the white 
solid left behind was the boronate ester (4.95 g, quant.). The boronate ester (1 g, 4.58 mmol) was 
then dissolved in pyridine (15 mL) at room temperature, then benzoyl chloride (0.51 mL, 0.62 g, 
4.41 mmol) was added, and the mixture was allowed to stir for 12 h at room temperature. After 
the reaction was finished, pyridine was evaporated off under reduced pressure, the residue was 
dissolved in benzene and was filtered. The filtrates were concentrated in vacuo and dried under 
high vacuum for 12 h. Then, it was dissolved in minimum amount of benzene at 80 °C and was 
allowed to cool down gradually overnight, the solids were filtered out and washed with hexane to 
give 9 (1.12g, 76%). 
	
	
(3R,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)cyclohexyl benzoate (10):  
 
 
 
 
 
Compound 9 (500 mg, 1.55 mmol) was first dissolved in CH2Cl2 (15 mL), at room temperature, 
under argon, then pinacol (365 mg, 3.0 mmol) was added followed by BF3.OEt2 (32 mL, 0.77 
mmol). This mixture was stirred for 4 h at room temperature, then the solvent was evaporated off 
under reduced pressure, the left over gum was dissolved in methanol and evaporated under reduced 
pressure, this process was repeated for five times, and then the left over sticky substance was 
OCOPh
OTBSTBSO
OO B
Ph
OCOPh
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treated as the crude for the next step. The crude product was dissolved in DMF (15.5 mL) at 0 °C. 
To the mixture was added tetrabutyl ammonium bromide (48 mg, 0.15 mmol), DMAP (189 mg, 
1.55 mmol), and TBSCl (2.34 g, 15.5 mmol), then triethylamine (0.59 mL, 434 mg, 4.27 mmol) 
was added drop wise, after the addition was over the reaction was raised at room temperature, and 
allowed to stand at room temperature for 15 h. After the reaction was finished, water (75 mL) was 
added to the reaction, and then the aqueous layer was extracted with CH2Cl2 for three times. The 
combined organic layer was washed with water for three times, and then was washed with brine, 
dried over MgSO4, filtered and evaporated in vacuo. The residue was purified by silica gel column 
(5% ethyl acetate-hexanes) to give 10 (372 mg, 2 steps 52%).  Spectral data for 10: 1H NMR (300 
MHz, CDCl3) d 7.60-7.33 (5H, m), 5.06-4.89 (1H, m), 3.74-3.63 (2H, m), 2.27-2.04 (3H, m), 1.66-
1.39 (3H, m), 0.87 (18H, s), 0.06 (12H, s); 13C NMR (75 MHz, CDCl3) d 165.98, 134.83, 133.06, 
131.3, 130.64, 129.68, 70.75, 68.62, 66.29, 45.85, 40.89, 25.90, 18.30, -4.54. HRMS ESI: m/z: 
calcd for C25H44Na1O4Si2: 487.2658 [M +Na]+, found 487.2676. 
 
 
(3R,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)cyclohexanone (7):  
 
 
 
 
 
To a solution of 10 (500 mg, 1.08 mmol) in CH2Cl2 (22 mL) was added a solution of NaOH (260 
mg, 6.5 mmol) in MeOH (44 mL), dropwise at 0 °C.  The resulting mixture was allowed to stand 
overnight, the reaction was quenched with 1M HCl solution, the aqueous layer was washed with 
CH2Cl2 twice, the combined organic layer was washed with water, followed by brine, dried over 
MgSO4, filtered and evaporated under reduced pressure.  The residue was dissolved in CH2Cl2 (11 
mL), and to the solution was added NaOAc (44 mg, 0.54 mmol) and PCC (395 mg 1.87 mmol) at 
0 °C and the resulting mixture was stirred for 15 min. The reaction mixture was filtered through a 
pad of Celite, the filtrates were washed with saturated Na2S2O3 solution, the aqueous layer was 
extracted with CH2Cl2. The combined organic layer was washed with brine, dried over MgSO4, 
filtered and evaporated in vacuo. The residue was purified on silica gel column (2% ethyl acetate-
hexanes) to give ketone 7 (217 mg, 2 steps 56%). Spectral data for 7: 1H NMR (300 MHz, CDCl3) 
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d 3.83-3.73 (2H, m), 2.56-2.50 (1H, dd, J = 5.2, 14.1 Hz), 2.38-2.30 (2H, t, J = 11.0 Hz), 2.29-
2.22 (1H, m), 1.82-1.71 (1H, dd, J = 11.0, 12.7 Hz), 0.86 (18H, s), 0.06 (12H, s); 13C NMR (75 
MHz, CDCl3) d 207.67, 66.85, 51.00, 45.11, 25.81, 18.13, -4.68. HRMS ESI: m/z: calcd for 
C18H38Na1O3Si1: 381.2298 [M +Na]+, found 381.2257. 
 
 
Methyl (1S,3R,4S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-1,4-dihydroxycyclohexane-1-
carboxylate (17): 
 
 
 
 
 
To a solution od D-(-)-quinic acid (10g, 52 mmol) in MeOH (37 mL) was added SO2Cl2 (1 mL) 
dropwise at room temperature. The resulting mixture was allowed to stand overnight, at the next 
day MeOH was evaporated under reduced pressure and the glue like leftover was again dissolved 
in MeOH and evaporated again. This process was repeated for five times.  Finally, the sticky left 
over was dissolved in DMF (200 mL) and to the solution was added TBSCl (17.25 g, 114.5 mmol), 
tetrabutyl ammonium bromide (1.7 g, 5.27 mmol), triethyl amine (16.5 mL, 118.2 mmol) and 
DMAP (0.65 g, 5.32 mmol) at 0 °C. The resulting mixture was allowed to rise at room temperature 
over 18 h. The reaction was quenched with water, the aqueous layer was washed with CH2Cl2 five 
times, and the combined organic layer was washed with water, followed by brine, dried over 
MgSO4, filtered and evaporated under reduced pressure. Ther residue was purified on a silica gel 
column using (12% ethyl acetate-hexanes) to give ester 17 (11.8g, 2 steps, 52%).  
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Methyl (1S,3R,4S,5R)-4-((1H-imidazole-1-carbonothioyl)oxy)-3,5-bis((tert-
butyldimethylsilyl)oxy)-1-hydroxycyclohexane-1-carboxylate (18): 
 
 
 
 
 
To a solution of ester 17 (11.8 g, 27.1 mmol) in CH2Cl2 (14 mL) was added TCDI (7.3 g, 40.6 
mmol) and DMAP (330 mg, 2.7 mmol) at room temperature. The resulting mixture was allowed 
to stand at that temperature for 20 h. The reaction mixture was concentrated by evaporation in 
vacuo. The left over crude was then purified on a silica gel column (16-18% ethyl acetate-hexanes) 
to afford pure compound 18 (13.2g, 89%).  
 
 
Methyl (3S,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)-1-hydroxycyclohexane-1-carboxylate 
(19): 
 
 
 
 
To a solution of compound 18 (6.56 g, 12.0 mmol) in 2-methoxymethanol (70 mL) was added 
NaH2PO2·xH2O (5.29 g, 60.0 mmol) under reflux condition. In another flask AIBN (395 mg, 2.4 
mmol) was dissolved in 2-methoxyethanol (10 mL). This solution was added to the solution of 
compound 18 by two fraction over 3 h. The reaction was cooled to the room temperature and was 
quenched with sat. NH4Cl, the aqueous layer was extracted with EtOAc for three times. The 
combined organic layer was washed with water followed by bine, and was dried over MgSO4, 
filtered and evaporated in vacuo. The crude was purified on a silica gel column (6% ethyl acetate-
hexanes) to get the pure deoxygenated compound 19 (2.87g, 57%).  
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 (3S,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)-1-(hydroxymethyl)cyclohexan-1-ol (20): 
 
 
 
 
 
To a solution of compound 19 (3.2 g, 7.7 mmol) in EtOH (20 mL) was added NaBH4 (878 mg, 
23.5 mmol) at 0 °C. The resulting mixture was allowed to stand for 2.5 h at that temperature. To 
the reaction mixture was added brine, and the aqueous layer was extracted with EtOAc twice. The 
combined organic layer was washed with water and brine, dried on MgSO4, filtered and evaporated 
in vacuo. The crude was purified on a silica gel column (20% ethyl acetate-hexanes) to give the 
pure diol 20 (2.53g, 85%).  
	
 
(((7S,9S)-2-phenyl-1,3-dioxaspiro[4.5]decane-7,9-diyl)bis(oxy))bis(tert-butyldimethylsilane) 
(21):  
 
 
 
 
To a solution of 20 (2.53 g, 6.47 mmol) in CH2Cl2 (64.7 mL) was added activated 4Å molecular 
sieves (3.23 g), benzaldehyde dimethyl acetal (1.24 mL, 1.27 g, 8.41 mmol), and the mixture was 
stirred for 12 h at room temperature. The reaction mixture was filtered through a pad of Celite, the 
filtrate was washed with water, aqueous layer was extracted with CH2Cl2 for three times. 
Combined organic layer was washed with water and brine, dried on MgSO4, filtered and 
evaporated in vacuo. The residue was purified on silica gel column (2% ethyl acetate-hexanes) to 
give 21 (2.54 g, 82%) as a mixture of two diastereomers. Spectral data for 21: 1H NMR (300 MHz, 
CDCl3) d 7.50-7.46 (2H, m), 7.41-7.34 (3H, m), 5.92 (5.81) (1H, s), 4.26-4.25 (1H, m), 4.08- 3.98 
(2H, m), 3.92-3.68 (1H, m), 2.28 (2.17) (1H, d, J = 11.9 Hz), 1.97-1.84 (3H, m), 1.67-1.59 (1H, 
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m), 1.48-1.34 (1H, m), 0.90 (18H, d, J = 5.9 Hz), 0.1-0.05 (12H, q, J = 6.4 Hz); 13C NMR (75 
MHz, CDCl3) d 138.71 (138.11), 129.29 (129.15), 128.43, 126.79 (126.58), 102.57 (101.49), 81.52 
(80.99), 75.29, 67.38 (67.16), 66.09 (65.83), 46.34 (44.42), 42.73 (42.68), 41.89 (41.80), 25.99, 
25.89, 18.27, 18.05, -4.54, -4.83. HRMS ESI: m/z: calcd for C26H46Na1O4Si2: 501.2805 [M +Na]+, 
found 501.2832. 
 
 
(7S,9S)-9-((tert-butyldimethylsilyl)oxy)-2-phenyl-1,3-dioxaspiro[4.5]decan-7-ol (22):  
 
 
 
 
 
 
To a solution of 21 (1.15 g, 2.4 mmol) in THF (48 mL) was added TBAF (1M in THF, 2.4 mL, 
2.4 mmol) at 0 °C dropwise over 1 h.  The reaction was monitored by TLC carefully. At the point 
of polar bis-TBS deprotected spot appearance on TLC, the reaction was quenched with saturated 
NH4Cl. The aqueous layer was extracted with ethyl acetate for three times, and the combined 
organic layer was washed with water, followed by brine, dried over MgSO4, filtered and 
evaporated in vacuo. The residue was chromatographed on silica gel column (10-15% ethyl 
acetate-hexanes) to give 22 as four diastereomers mixtures (399 mg, 70%, brsm). Spectral data for 
22: 1H NMR (300 MHz, CDCl3) d 7.50-7.46 (2H, m), 7.40-7.36 (3H, m), 5.85 (1H, s), 4.34-4.26 
(1H, m), 4.17-4.08 (1H, m), 4.02 (1H, d, J = 8.6 Hz), 3.80 (1H, d, J = 8.9 Hz), 2.07 (1H, dd, J = 
3.4, 13.4, Hz), 2.00-1.66 (5H, m), 0.89 (9H, s), 0.09 (6H, s); 13C NMR (75 MHz, CDCl3) d 137.63, 
129.56, 128.52, 126.73, 103.22, 82.46, 67.20, 65.11, 44.29, 42.31, 40.06, 25.43, 18.19, -4.69, -
4.73. HRMS ESI: m/z: calcd for C20H32Na1O4Si1: 387.1994 [M +Na]+, found 387.1976. 
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(R)-9-((tert-butyldimethylsilyl)oxy)-2-phenyl-1,3-dioxaspiro[4.5]decan-7-one (23): 
 
 
 
 
 
To a solution of alcohol 22 (410 mg, 1.1 mmol) in CH2Cl2 (11 mL) was added activated molecular 
sieves (553 mg) and N-morpholeneoxide (322 mg, 2.75 mmol) at 0 °C under argon. After stirring 
for 30 min, TPAP (39 mg, 0.11 mmol) was added to the mixture, and the resulting mixture was 
stirred at 0 °C for another 3 h.  The reaction mixture was filtered through a short silica gel column 
(6-8% ethyl acetate-hexanes) to give 23 (407mg, 99%). Spectral data for 23: 1H NMR (300 MHz, 
CDCl3) d 7.46-7.42 (2H, m), 7.39-7.35 (3H, m), 5.88 (1H, s), 4.39-4.31 (1H, m), 4.00 (1H, d, J = 
8.6 Hz), 3.78 (1H, d, J = 8.6 Hz), 2.69-2.60 (3H, m), 2.43-2.31 (2H, m), 2.03-1.96 (1H, m), 0.87 
(9H, s), 0.05 (6H, s); 13C  NMR (75 MHz, CDCl3) d 206.06, 137.78, 129.46, 128.50, 126.55, 
103.25, 81.18, 75.25, 66.86, 50.16, 49.75, 43.54, 25.83, 18.10, -4.78, -4.82. HRMS ESI: m/z: calcd 
for C20H30Na1O4Si1: 385.1851 [M +Na]+, found 385.1811. 
 
 
 (7R,9S)-9-((tert-butyldimethylsilyl)oxy)-2-phenyl-1,3-dioxaspiro[4.5]decan-7-ol (24): 
 
 
 
 
 
  
To a mixture of ketone 23 (400 mg, 1.1 mmol) and ZnCl2 (300 mg, 2.2 mmol) in CH2Cl2 (11 mL) 
was added DIBAL-H (4.4 mL, 1M in toluene) at -78 °C dropwise, and the resulting mixture was 
stirred at -78 °C for 12 h. To the reaction mixture was added MeOH (3 mL) at -78 °C, and the 
resultant mixture was warmed to room temperature. Then, saturated Rochelle salt solution (5.2 
mL) was added, and allowed to stir for 30 min. The aqueous layer was extracted with CH2Cl2 for 
three times. The combined organic layer was washed with saturated Rochelle salt and brine, dried 
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over MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed on silica gel 
column (6-8% and 9-10% ethyl acetate-hexanes) to give trans alcohols 22 (less polar, 115 mg, 
29%) and cis alcohols 24 (more polar, 226 mg, 67%). Spectral data for 24: 1H NMR (300 MHz, 
CDCl3) d 7.48-7.44 (2H, m), 7.41-7.32 (3H, m), 5.85 (1H, s), 4.13-4.02 (3H, m), 3.85 (1H, d, J = 
8.3 Hz), 2.13-2.00 (3H, m), 1.64-1.43 (3H, m), 0.89 (9H, s), 0.07 (6H, s); 13C NMR (75 MHz, 
CDCl3) d 137.91, 129.47, 128.49, 126.79, 103.35, 80.40, 67.35, 66.71, 44.36, 42.91, 42.34, 25.94, 
18.19, -4.69, -4.76. HRMS ESI: m/z: calcd for C20H32Na1O4Si1: 387.1994 [M +Na]+, found 
387.1966. 
 
 
(1R,3S)-3-((tert-butyldimethylsilyl)oxy)-5-oxocyclohexyl benzoate (26): 
 
 
 
 
 
 To a solution of cis alcohols 24 (219 mg, 0.6 mmol) in CH2Cl2 (5 mL) was added benzoyl chloride 
(0.15 mL, 186 mg, 1.32 mmol), triethylamine (0.24 mL, 182 mg, 1.8 mmol), and DMAP (102 mg, 
0.84 mmol) at room temperature under argon, and the resultant mixture was stirred for 4 h. To the 
reaction mixture was added saturated NH4Cl, and the aqueous layer was extracted with CH2Cl2 for 
three times. Combined extracts were washed with water and brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was chromatographed on the silica gel column (5% ethyl 
acetate-hexanes) to give benzoate-protected cis alcohols 25 (264 mg, 94%). The mixture of 
benzoate-protected cis alcohols (264 mg, 0.564 mmol) was dissolved in THF (6mL) under argon, 
and 10% Pd(OH)2 (26 mg) was added, then argon was purged with hydrogen gas, and the reaction 
mixture was allowed to stir under the hydrogen atmosphere for 8 h. The reaction mixture was 
filtered through a pad of Celite, and filtrates were concentrated in vacuo. The residue was dissolved 
in MeOH (28 mL), and a saturated aqueous solution of NaIO4 (542 mg, 2.53 mmol, in 0.28 mL 
H2O) was added, the resulting mixture was stirred for 3 h. To the reaction mixture was added 
water, and aqueous layer was extracted with ethyl acetate until no product was found in the 
aqueous layer, on TLC. The extracts were washed with brine, dried over MgSO4, filtered and 
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concentrated in vacuo). The residue was chromatographed on silica gel column (2% ethyl acetate-
hexanes) to give ketone 26 (158 mg, 64%). Spectral data for 26: 1H NMR (400 MHz, CDCl3) d 
8.01 (2H, d, J = 8.2 Hz), 7.54 (1H, t, J = 7.3 Hz), 7.42 (2H, t, J = 7.8 Hz), 5.29-5.22 (1H, m), 4.12-
4.05 (1H, m), 2.81 (1H, dd, J = 5.5, 13.5 Hz), 2.64 (1H, dd, J = 5.0, 15.2 Hz), 2.59-2.53 (1H, m), 
2.48-2.42 (2H, m), 2.08-2.00 (1H, m), 0.83 (9H, s), 0.03 (6H, s); 13C NMR (100 MHz, CDCl3) d 
205.67, 165.66, 133.27, 129.69, 129.78, 128,45, 68.15, 66.34, 50.61, 46.30, 39.50, 25.77, 18.07. -
4.77, -4.71. HRMS ESI: m/z: calcd for C19H28Na1O4Si: 371.1655 [M +Na]+, found 371.1655. 
 
 
(1S,3R,E)-3-((tert-butyldimethylsilyl)oxy)-5-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methyl-6-
((triethylsilyl)oxy)heptan-2-yl)hexahydro-1H-inden-4(2H)-ylidene)ethylidene)cyclohexyl 
benzoate (28a): 
  
 
 
 
 
 
 
& (1R,3S,E)-3-((tert-butyldimethylsilyl)oxy)-5-((E)-2-((1R,7aR)-7a-methyl-1-((R)-6-methyl-
6-((triethylsilyl)oxy)heptan-2-yl)hexahydro-1H-inden-4(2H)-ylidene)ethylidene)cyclohexyl 
benzoate (28b):  
 
 
 
 
 
 
 
To a mixture of CD-ring synthon 27 (36 mg, 59 µmol) and ketone 26 (14 mg, 39 µmol) in THF 
(0.6 mL) was added LiHMDS (79 µL, 78 µmol) was slowly at -78 °C under argon, and the mixture 
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was stirred for 2.5 h, then the mixture was raised at room temperature and allowed to stand for 10 
min.  To the reaction mixture was added water, and extracted with ether for three times. The 
combined extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo.  
The residue was passed through a small silica gel column to give 28 as two diastereomer mixture 
(35 mg, 72%). These diastereomers were separated on a silica gel column (0.3% ether-hexane) to 
give 28a (18 mg, 36%) and 28b (17 mg, 35%). Spectral data for 28a: 1H NMR (400 MHz, CDCl3) 
d 8.05 (2H, d, J = 6.9 Hz), 7.55 (1H, t, J = 7.3 Hz), 7.44 (2H, t, J = 7.8 Hz), 6.26 (1H, d, J = 10.9 
Hz), 5.80 (1H, d, J = 11.5 Hz), 4.91-4.90 (1H, m), 3.71-3.67 (1H, m), 3.13 (1H, dd, J = 4.6, 12.8 
Hz), 2.80 (1H, d, J = 11.5 Hz), 2.45 (1H, dd, J = 4.6, 13.1 Hz), 2.36 (1H, m), 2.14 (1H, t, J = 11.9 
Hz), 2.02-1.86 (3H, m), 1.67-1.60 (4H, m), 1.41-1.24 (13H, m), 1.17 (6H, s), 0.96-0.82 (22H, m), 
0.58-0.52 (9H, m), 0.07 (6H, d, J = 6.9 Hz); 13C NMR (100 MHz, CDCl3) d 165.98, 143.35, 132.99, 
130.65, 130.23, 129.72, 128.42, 123.05, 115.57, 73.59, 70.49, 68.76, 56.73, 56.46, 46.45, 45.94, 
45.62, 41.85, 40.62, 36.55, 36.22, 33.74, 30.11, 29.93, 28.97, 27.73, 25.95, 23.59, 22.39, 20.94, 
18.92, 18.21, 12.26, 7.24, 6.91, -4.48, -4.54. HRMS ESI: m/z: calcd for C45H76Na1O4Si2: [M +Na]+ 
759.5180, found 759.5205. Spectral data for 28b: 1H NMR (400 MHz, CDCl3) d 8.04 (2H, d, J = 
7.3 Hz), 7.55 (1H, t, J = 7.8 Hz), 7.44 (2H, t, J = 7.8  Hz), 6.29 (1H, d, J = 10.9 Hz), 5.84 (1H, d, 
J = 11.5 Hz), 4.91-4.88 (1H, m), 3.62-3.58 (1H, m), 2.99 (1H, dd, J = 4.6, 10.9 Hz), 2.79 (1H, d, 
J = 12.4 Hz), 2.66 (1H, dd, J= 4.6, 12.4 Hz), 2.37-2.34 (1H, br), 2.25-2.20 (1H, t, J = 11.5 Hz), 
2.02-1.66 (9H, m), 1.43-1.30 (7H, m), 1.19 (6H, s), 0.96-0.83 (23H, m), 0.59-0.53 (9H, m), 0.09-
0.07 (6H, d, J = 8.2 Hz); 13C NMR (100 MHz, CDCl3) d 165.96, 143.38, 132.96, 130.62, 130.38, 
129.68, 128.39, 123.05, 115.54, 73.56, 71.04, 68.60, 56.73, 56.41, 45.84, 45.61, 42.07, 41.76, 
40.56, 38.32, 36.53, 36.23, 30.09, 29.92, 29.79, 28.99, 27.78, 25.96, 23.63, 22.23, 20.93, 18.91, 
18.29, 12.15, 7.22, 6.89, -4.59, -4.67. HRMS ESI: m/z: calcd for C45H76Na1O4Si2: 759.5180. [M 
+Na]+, found: 759.5170 
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(1R,3S,E)-5-((E)-2-((1R,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-
1H-inden-4(2H)-ylidene)ethylidene)cyclohexane-1,3-diol (5a):  
 
 
 
 
 
 
 
To a solution of 28a (18 mg, 24 µmol) in MeOH (0.6 mL) and THF (2.4 mL) was added K2CO3 
(5 mg, 36 µmol) at room temperature under argon, and the mixture was stirred overnight. To the 
reaction mixture was added saturated NH4Cl, and aqueous layer was extracted with ethyl acetate 
for three times. The combined organic layer was washed with water and brine, dried over MgSO4, 
filtered and concentrated in vacuo.  The residue was purified by silica gel column (10% ethyl 
acetate-hexanes) to give alcohol, which was then dissolved in THF (1 mL), and HF·Py (181 mg, 
0.16 mL, 6.3 mmol) was added, and the resulting mixture was stirred for 24 h at room temperature. 
To the reaction mixture was added saturated Na2S2O3, and aqueous layer was extracted with ethyl 
acetate for three times. The extracts were washed with water and brine, dried over MgSO4, filtered 
and concentrated in vacuo. The residue was first eluted using 3% MeOH-CH2Cl2 on a silica gel 
column, and then again purified on a preparative TLC plate using 5% MeOH-CH2Cl2 as the mobile 
phase to give 5a (5 mg, 56%). Spectral data for 5a: 1H NMR (400 MHz, CDCl3) d 6.23 (1H, d, J 
= 10.9 Hz), 5.86 (1H, d, J = 11.5 Hz), 3.91 (2H, m), 2.82 (1H, dd, J = 10.3, 4.1 Hz), 2.59 (1H, dd, 
J = 11.5, 3.7 Hz), 2.49 (1H, dd, J = 13.3, 3.7 Hz), 2.43-2.38 (1H, m), 2.28-2.23 (1H, m), 2.13-1.24 
(27H, m), 1,22 (6H, s), 0.94 (3H, d, J = 6.4 Hz), 0.55 (3H, s); 13C NMR (100 MHz, CDCl3) d 
142.89, 130.21, 123.82, 115.48, 71,22, 68.92, 68.65, 56.61, 56.41, 45.87, 45.23, 44.50, 41.33, 
40.59, 36.95, 36.48, 36.18, 29.46, 29.28, 28.99, 27.75, 23.57, 22.37, 20.89, 18.89, 12.16. HRMS 
ESI: m/z: calcd for C26H44Na1O3: [M +Na]+ 427.3188.,found  427.3172  
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(1R,3S,Z)-5-((E)-2-((1R,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-
1H-inden-4(2H)-ylidene)ethylidene)cyclohexane-1,3-diol (5b):   
 
 
 
 
 
 
 
Similar to 28a, compound 28b (17 mg, 24 µmol) in MeOH (0.6 mL) and THF (2.4 mL) was added 
K2CO3 (4.9 mg, 36 µmol) at room temperature under argon, and the mixture was stirred overnight. 
To the reaction mixture was added saturated NH4Cl, and aqueous layer was extracted with ethyl 
acetate for three times. The combined organic layer was washed with water and brine, dried over 
MgSO4, filtered and concentrated in vacuo.  The residue was purified by silica gel column (10% 
ethyl acetate-hexanes) to give alcohol, which was then dissolved in THF (1 mL), and HF·Py (0.16 
mL) was added, and the resulting mixture was stirred for 24 h at room temperature. To the reaction 
mixture was added saturated Na2S2O3, and aqueous layer was extracted with ethyl acetate. The 
extracts were washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo. 
The residue was first eluted using 3% MeOH-CH2Cl2 on a silica gel column, and then again 
purified on a preparative TLC plate using 5% MeOH-CH2Cl2 as the mobile phase to give 5b (5.5 
mg, 59%). Spectral data for 5b: 1H NMR (400 MHz, CDCl3) d 6.34 (1H, d, J = 10.9 Hz), 5.87 
(1H, d, J = 11.5 Hz), 4.01 (2H, br), 2.83 (1H, dd, J = 4.6, 10.3 Hz), 2.58 (1H, dd, J = 6.4, 13.5 Hz), 
2.32-2.24 (3H, m), 2.04-1.97 (3H, m), 1.91-1.84 (2H, m), 1.72-1.21 (23H, m), 0.94 (3H, d, J = 6.4 
Hz), 0.55 (3H, s); 13C NMR (100 MHz, CDCl3) d 142.89, 130.05, 124.14, 115.44, 71.22, 68.96, 
68.77, 56.58, 56.39, 45.85, 45.14, 44.50, 40.56, 40.36, 36.76, 36.47, 36.20, 29.44, 29.31, 29.02, 
27.78. 23.60, 22.37, 20.90, 18,89, 12.17. HRMS ESI: m/z: calcd for C26H44Na1O3: 427.3188 [M 
+Na]+, found 427.3196. 
 
 
 
 
Me
H
Me
OH
OHHO
	 60	
(1R,3aR,4S,7aR)-1-(1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol (Inhoffen 
Lythgoe Diol): 
 
 
 
 
To a solution of vitamin D2 (1.0 g, 2.54 mmol) in MeOH (84 mL) was added pyridine (0.84 mL). 
the resulting mixture was allowed to cool at -78 °C, and then oxygen gas was bubbled in the 
mixture for 10 mins. Ozone gas was bubbled in the reaction mixture at the same temperature until 
the color of the reaction has turned in to pale blue, at that point ozone flow was stopped and oxygen 
was flowed again for 10 mins. To the reaction mixture was added NaBH4 (952 mg, 25.4 mmol) 
and the resulting mixture was allowed to stand overnight at room temperature. MeOH was 
evaporated from the reaction mixture under reduced pressure, and the crude was diluted with 
EtOAc and water. The aqueous phase was extracted with EtOAc twice and the combined organic 
layer was washed with water and brine, dried over MgSO4, filtered and evaporated in vacuo. The 
crude compound was purified on a silica gel column (25% ethyl acetate-hexanes) to give the pure 
Inhoffen Lythgoe diol (410 mg, 77%). 
 
 
2-((1R,3aR,4S,7aR)-7a-methyl-4-((triethylsilyl)oxy)octahydro-1H-inden-1-yl)propyl 4-
methylbenzenesulfonate (29): 
 
 
 
 
To a solution of Inhoffen Lythgoe diol (1 g, 4.7 mmol) in Pyridine (9 mL) was added TsCl (1.34 
g, 7.05 mmol) at room temperature the resulting mixture was allowed to stand at that temperature 
for 1.5 h.. To the reaction was added water, the aqueous layer was extracted with EtOAc twice, 
the combined organic layer was washed with water and brine, dried on MgSO4, filtered and 
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evaporated in vacuo to give the crude, the crude compound was purified on a silica gel column 
(10% ethyl acetate-hexanes) to give the Tosylate (1.7 g). 
To the tosylate (1.7 g, 4.63 mmol) in CH2Cl2 (10 mL) was added TESOTf (1.36 mL, 6.09 mmol) 
and 2,6-lutidine (1.25 mL, 9.3 mmol) dropwise at 0 °C. The reaction mixture was allowed to stand 
at that temperature for one hour. The reaction was quenched with water; the aqueous layer was 
extracted with CH2Cl2 twice. The combined organic layer was washed with water and brine, dried 
on MgSO4, filtered and evaporated in vacuo. The crude was purified on the silica gel column (5% 
ethyl acetate-hexanes) to afford the pure compound 29 (2.5g, 2 steps, 89%). 
 
 
3-((1R,3aR,4S,7aR)-7a-methyl-4-((triethylsilyl)oxy)octahydro-1H-inden-1-yl)butanal (30): 
 
 
 
 
To a solution of compound 29 (1.87 g, 3.91 mmol) in super dehydrated DMSO (26 mL) was added 
NaCN (248 mg, 5 mmol) at 90 °C.  The resulting mixture was allowed to stand at that temperature 
for 3 h. the reaction mixture was cooled to the room temperature and water was added to the 
reaction. The aqueous layer was extracted with ether until no product could be traced in the 
aqueous phase. The cobined organic layer was washed with water and brine, dried over MgsO4, 
filtered and evaporated in vacuo. The crude compound was purified on the silica gel column ( 4% 
ethyl acetate – hexanes) to get the pure compound (930 mg, 73%) 
To the cyanide (329 mg, 0.98 mmol) in CH2Cl2 (10 mL) was added DIBAL-H (1M in toluene, 
1.96 mL) dropwise at -10 °C. The resulting solution was allowed to stand at that temperature for 
1 h, then it was raised at room temperature. To the reaction was added MeOH (1.4 mL), and the 
reaction was allowed to stand for 30 mins, after that sat. Rochelle’s salt solution (2.4 mL) was 
added and the reaction was allowed to stand for 30 mins. The aqueous layer was washed with sat. 
Rochelle’s salt and  brine, dried on MgSO4, filtered and evaporated in vacuo to afford the crude 
aldehyde The crude compound was purified on a silica gel column (10% ethyl acetate-hexanes) to 
give pure aldehyde 30 (278 mg, 84%). 
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Ethyl 2,2-difluoro-3-hydroxy-5-((1R,3aR,4S,7aR)-7a-methyl-4-((triethylsilyl)oxy)octahydro-
1H-inden-1-yl)hexanoate (31): 
 
 
 
 
 
To a solution of activated Zn (243.7 mg, 6.13 mmol) in THF (6.2 mL) was added 
ethylbromodifluoroacetate (0.46 mL, 6.13 mmol). The resulting mixture was refluxed for 20 mins 
and then was cooled to 0 °C. to this solution was added another solution of compound 30 (250 mg, 
1.3 mmol) in THF (7.5 mL). The resulting mixture was heated to reflux for another 20 mins, and 
then was cooled to r.t. The reaction mixture was poured into 1M KHSO4 solution, the aqueous 
layer was extracted with EtOAc twice and the combined organic layer was washed with water and 
brine, dried over MgSO4, filtered and evaporated in vacuo. The crude compound was purified on 
a silica gel column (7-9% ethyl acetate-hexanes) to get compound 31 as a mixture of two 
diastereomers (235 mg, 69%) 
 
 
Ethyl 3-((1H-imidazole-1-carbonothioyl)oxy)-2,2-difluoro-5-((1R,3aR,4S,7aR)-7a-methyl-4-
((triethylsilyl)oxy)octahydro-1H-inden-1-yl)hexanoate (32): 
 
 
 
 
 
To a solution of difluoroester 31 (318.7 mg, 0.69 mmol) in CH2Cl2 (7 mL) was added TCDI 
(184.44 mg, 1.03 mmol) and DMAP (8.4 mg, 0.069 mmol) at room temperature. The reaction was 
allowed to stand at that temperature for 3 days. CH2Cl2 was evaporated under reduced pressure to 
give the crude compound. The crude was purified on a silica gel column (10% ethyl acetate-
hexanes) to give pure compound 32 (284 mg, 72%) 
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Ethyl 2,2-difluoro-5-((1R,3aR,4S,7aR)-7a-methyl-4-((triethylsilyl)oxy)octahydro-1H-inden-
1-yl)hexanoate (33): 
 
 
 
 
To a solution of compound 32 (210.9 mg, 0.37 mmol) in Et3SiH (3.25 mL) was added a solution 
of benzoyl peroxide (36 mg, 0.15 mmol) in Toluene (0.5 mL) in three portion over 2.5 h under 
reflux condition. The resulting mixture was concentrated in vacuo and the left over material was 
treated as the crude. The crude compound was purified on a silica gel column (5% ethyl acetate-
hexanes) to give pure compound 33 (151 mg, 92%). 
 
 
3,3-difluoro-2-methyl-6-((1R,3aR,4S,7aR)-7a-methyl-4-((triethylsilyl)oxy)octahydro-1H-
inden-1-yl)heptan-2-ol (34): 
 
 
 
 
To a solution of ester 33 (153.4 mg,  0.35 mmol) in THF (5 mL) was added 1M solution of MeMgI 
(0.735 mL) at 0 °C. the reaction was allowed to stand at that temperature for 1 h. To the reaction 
was added sat. NH4Cl, the aqueous layer was extracted with ether twice, the combined organic 
layer was washed with water and brine, dried over MgSO4, filtered and evaporated in vacuo. The 
crude product was purified on a silica gel column (7% ethyl acetate – hexanes) to give pure alcohol 
34 (120.4 mg, 81%) 
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(1R,3aR,7aR)-1-(5,5-difluoro-6-methyl-6-((trimethylsilyl)oxy)heptan-2-yl)-7a-
methyloctahydro-4H-inden-4-one (35): 
 
 
 
 
To a solution of alcohol 34 (298.5 mg, 0.69 mmol) in THF (14 mL) was added 1 M TBAF in THF 
(11.4 mL) dropwise at 25 °C. The reaction was allowed to stand at that temperature for 3.5 h. To 
the reaction was added water, the aqueous layer was extracted with ether twice, the combined 
organic layer was washed with water and brine, dried over MgSO4, filtered and evaporated in 
vacuo. The crude was purified on the silica gel column (20% ethyl acetate – hexanes) to give the 
pre diol (188.9 mg, 86%). 
 
To a solution of diol (203.9 mg, 0.64 mmol) in CH2Cl2 (6.4 mL) was added activated molecular 
sieves (320 mg) and NMO (149.9 mg, 1.28 mmol) at 0 °C. the resulting mixture was allowed to 
stand at that temperature for 30 mins and then TPAP (9 mg, 0.03 mmol) was added to the mixture. 
The resulting mixture was allowed to stand for 3 h at that temperature. The reaction mixture was 
poured on a small silica gel column (15-20% ethyl acetate – hexanes) to get the pure ketone. (202 
mg, quant). 
 
To a solution of ketone (183.8 mg, 0.58 mmol) in CH2Cl2 (12.6 mL) was added TMS-I (0.45 mL, 
3.07 mmol) at 0 °C. The resultant mixture was allowed to raise at room temperature over 8  h. 
Water was added to the mixture and the aqueous layer was extracted with CH2Cl2 twice. The 
combined organic layer was washed with water and brine, dried over MgSO4, filtered and 
evaporated in vacuo to give the crude product. The crude was purified on a silica gel column (5% 
ethyl acetate – hexanes) to give pure Grundmann’s ketone derivative 35 (225.6 mg, quant). 
Spectral data for 35: 1H NMR (400 MHz, CDCl3) d 2.45-2.40 (1H, m), 2.27-2.07 (3H, m), 2.00-
1.81 (3H, m), 1.73-1.31 (5H, m), 1.25 (7H, s), 0.94 (3H, d, J = 5.95 Hz), 0.62 (3H, s), 0.10 (9H, 
s); 13C NMR d 211.95, 125.17 (t, 1JCF = 249.2 Hz), 76.02 (t, 1JCF = 27.8 Hz), 61.98, 56.63, 49.95, 
41.02, 39.03, 35.45, 27.55, 27.47, 27.30, 29.06, 26.98, 24.54, 24.46, 24.11, 19.13, 18.58, 12.56, 
2.39. HRMS ESI: m/z calcd for C21H38F2Na1O2Si1: 411.2498 [M+ Na]+, found 411.2495. 
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Ethyl 2-((1R,7aR,E)-1-((R)-5,5-difluoro-6-methyl-6-((trimethylsilyl)oxy)heptan-2-yl)-7a-
methyloctahydro-4H-inden-4-ylidene)acetate (36):  
 
 
 
To a mixture of compound 35 (126.1 mg, 0.32 mmol) in THF (3 mL) was added NaH (60% mineral 
oil dispersion, 45.5 mg, 1.88 mmol) at 0 °C under argon. The resulting mixture was allowed to 
stand at that temperature for 30 min, then triethyl phosphanoacetate (481.1 mg, 0.4 mL, 2.14 
mmol) was added to the mixture with dropwise, upon completion of addition the mixture was 
allowed to stir at room temperature for 3 days. To the reaction was added saturated NH4Cl, and 
the aqueous layer was extracted with ethyl acetate for three times. The combined organic layer 
was washed with water and brine, then dried over MgSO4, filtered and concentrated in vacuo. The 
crude was then chromatographed on silica gel column (5% ethyl acetate-hexanes) to give 36 (134 
mg, 91%). Spectral data for 36: 1H NMR (400 MHz, CDCl3) d 5.45 (1H, s), 4.19-4.08 (2H, q, J = 
5.8 Hz), 2.11-2.08 (1H, t, J = 9.6 Hz), 2.01 (1H, d, J = 13.3 Hz), 1.95-1.92 (2H, m), 1.75-1.55 (6H, 
m), 1.53-1.34 (7H, m), 1.29-1.25 (11H, m), 0.93 (3H, d, J = 5.9 Hz), 0.58 (3H, s); 13C NMR d (100 
MHz, CDCl3) d 167.01, 163.32, 125.25 (t, 1JCF = 248.2 Hz), 112.13, 75.90 (t, 2JCF = 27.8 Hz), 
59.54, 56.89, 56.66, 47.14, 29.96, 29.66, 27.38, 27.33 (t, 2JCF = 24.9 Hz), 26.98, 24.54, 24.50, 
23.90, 22.21, 18.65, 2.40. HRMS ESI: m/z calcd for C25H44F2Na1O3Si1: 481.2917 [M+ Na]+, found 
481.2925. 
 
2-((1R,7aR,E)-1-((R)-5,5-Difluoro-6-methyl-6-((trimethylsilyl)oxy)heptan-2-yl)-7a-
methyloctahydro-4H-inden-4-ylidene)ethan-1-ol (37):  
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To a solution of compound 36 (228 mg, 0.5 mmol) in toluene (2.5 mL) was added DIBAL-H (1.49 
mL, 1.5 mmol) with dropwise at -78 °C under argon. The resultant mixture was then raised at room 
temperature and was allowed to stir for 2 h. MeOH (1 mL) was added to the mixture and stirred 
for additional 30 min. To this mixture, saturated Rochelle’s salt (1.8 mL) was added and stirred 
for another 30 min. The aqueous phase was then extracted with ethyl acetate for three times. 
Combined organic layer was washed with saturated Rochelle’s salt, saturated NH4Cl and brine, 
then dried over MgSO4, filtered and concentrated in vacuo. The residue was purified on silica gel 
column (16-18 % ethyl acetate-hexanes), to give pure alcohol 37 (157 mg, 76%). Spectral data for 
37: 1H NMR (300 MHz, CDCl3) d 5.22 (1H, t, J = 7.2 Hz), 4.19 (1H, d, J = 6.8 Hz), 2.61 (1H, dd, 
J = 4.5, 12.6 Hz), 2.13-1.37 (16 H, m), 1.28 (12H, s), 0.90 (3H, d, J = 6.2 Hz), 0.56 (3H, s); 13C 
NMR (75 MHz, CDCl3) d 143.74, 125.32 (t, 1JCF = 251.4 Hz), 119.38, 76.09 (t, 2JCF= 28.2 Hz), 
58.77, 56.48, 55.67, 45.42, 40.43, 35.92, 28.77, 27.66, 27.18 (t, 2JCF= 23.8 Hz), 24.60, 24.56, 
23.57, 22.24, 18.71, 11.94, 2.43; HRMS ESI: m/z calcd for C23H42F2Na1O2Si1: 439.2778 [M+ 
Na]+, found 439.2819. 
 
2-((2-((1R,7aR,E)-1-((R)-5,5-Difluoro-6-methyl-6-((trimethylsilyl)oxy)heptan-2-yl)-7a-
methyloctahydro-4H-inden-4-ylidene)ethyl)sulfonyl)benzo[d]thiazole (38):   
 
 
 
To a solution of alcohol 37 (148.8 mg, 0.36 mmol) in CH2Cl2 (1.2 mL) was added 2-mercapto 
benzothiazole (95.5 mg, 0.21 mmol) and PPh3 (149.8 mg, 0.21 mmol) at 0 °C under argon. To the 
resulting mixture was added diisopropyl azodicarboxylate (115.5 mg, 0.11 mL, 0.21 mmol) with 
dropwise, and the mixture was stirred for 15 min at 0 °C. Then, the reaction was concentrated in 
vacuo, and the residue was passed through a short silica gel column, the eluent was concentrated 
in vacuo to give crude product, which was subjected to the oxidation reaction at the next step. The 
crude thiol was dissolved in EtOH (3 mL) at 0 °C. Ammonium molybdate tetrahydrate (88.2 mg, 
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71 µmol) was added to the mixture, followed by a slow addition of 30% H2O2 (1 mL). The resulting 
mixture was then raised at room temperature and was allowed to stir for 3 h. To the reaction 
mixture was added saturated Na2S2O3 at 0 °C, and the aqueous layer was extracted with ethyl 
acetate for three times. The extracts were washed with water and brine, dried over MgSO4, filtered 
and concentrated in vacuo. The residu was purified on silica gel column (8% ethyl acetate- 
hexanes), to give 38 (214.8 mg, 2 steps 94%). Spectral data for 38: 1H NMR (400 MHz, CDCl3) d 
8.22 (1H, d, J = 7.8 Hz), 7.99 (1H, d, J = 7.8 Hz), 7.65-7.58 (3H, m), 5.01 (1H, t, J = 8.2 Hz), 4.26 
(1H, dd, J = 9.2, 14.2 Hz), 4.20 (1H, dd, J = 6.4, 14.2 Hz), 2.55 (1H, d, J = 14.2 Hz), 2.02-1.36 
(11H, m), 1.31-1.19 (12H, m), 0.93 (9H, t, J = 7.8 Hz), 0.86 (6H, d, J = 6.4 Hz), 0.58 (6H, q, J = 
7.8 Hz), 0.27 (3H, s); 13C NMR (100 MHz, CDCl3) d 152.91, 152.13, 127.96, 127.66, 125.45 (t, 
1JCF = 248.2 Hz), 122.32, 104.31, 77.1 (t, 1JCF = 31.6 Hz), 56.24, 56.05, 53.98, 45.82, 40.04, 35.67, 
29.10, 27.06 (t, 1JCF = 21.1 Hz), 24.65, 24.42, 23.27, 22.14, 18.63, 11.67, 7.01, 6.63. HRMS ESI: 
m/z calcd for C30H45F2N1Na1O3S2Si1: 620.2521 [M+ Na]+, found 620.2475. 
 
(1S,3R,E)-3-((tert-butyldimethylsilyl)oxy)-5-(2-((1R,7aR,E)-1-((R)-5,5-difluoro-6-methyl-6-
((trimethylsilyl)oxy)heptan-2-yl)-7a-methyloctahydro-4H-inden-4-
ylidene)ethylidene)cyclohexyl benzoate (39a) 
 
 
 
 & (1S,3R,Z)-3-((tert-butyldimethylsilyl)oxy)-5-(2-((1R,7aR,E)-1-((R)-5,5-difluoro-6-methyl-
6-((trimethylsilyl)oxy)heptan-2-yl)-7a-methyloctahydro-4H-inden-4-
ylidene)ethylidene)cyclohexyl benzoate (39b): 
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LiHMDS (1.3 M in hexane, 52 µL, 68 µmol) was slowly added to a mixture of CD-ring synthon 
38 (28.7 mg, 48 µmol) and ketone 26 (12 mg, 34 µmol) in THF (0.7 mL) at -78 °C under argon, 
and the mixture was stirred for 2.5 h, then the mixture was raised at room temperature and allowed 
to stand for 10 min.  To the reaction mixture was added water, and extracted with ether for three 
times. The combined organic layer was washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo.  The residue was passed through a small silica gel column to give 39 as two 
diastereomers mixture (31 mg, 92%). These diastereomers were separated on a silica gel column 
(0.5% ether-hexanes) to give 39a (15 mg, 46%) and 39b (16 mg, 46%). Spectral data for 39a: 1H 
NMR (300 MHz, CDCl3) d 8.03 (2H, d, J =7 .9 Hz), 7.55 (2H, t, J = 7.6 Hz), 7.43 (2H, t, J = 7.6 
Hz), 6.29 (1H, d, J = 11.4 Hz), 5.85 (1H, d, J = 11.4 Hz), 4.92-4.84 (1H, m), 3.64-3.57 (1H, m), 
2.98 (1H, dd, J = 4.1, 12.6 Hz), 2.79 (1H, dd, J = 3.8, 10.5 Hz), 2.66 (1H, dd, J = 4.5, 12.0 Hz), 
2.37-2.35 (1H, m), 2.23 (1H, t, J = 11.7 Hz), 2.05-1.82 (6H, m), 1.68 (4H, t, J = 11.7 Hz), 1.29 
(12H, s), 0.94 (3H, d, J = 6.2 Hz), 0.87 (9H, s), 0.56 (3H, s), 0.08 (6H, d, J = 6.2 Hz); 13C NMR 
(75 MHz, CDCl3) d 165.98, 143.21, 129.45, 132.99, 130.60, 129.69 (t, 1JCF = 249.3 Hz), 129.45, 
123.02, 115.64, 76.08 (t, 2JCF = 28.9 Hz), 71.04, 68.59, 56.48, 56.35, 45.84, 42.07, 41.76, 40.54, 
38.33, 35.96, 28.94, 27.31 (t, 2JCF = 20.9 Hz), 25.98, 24.57, 23.61, 22,20, 18.72, 18.32, 12.18, 2.46, 
-4.58, -4.66. HRMS ESI: m/z calcd for C42H68F2Na1O4Si2: 753.4521 [M+ Na]+, found 753.4536. 
Spectral data for 39b: 1H NMR (300 MHz, CDCl3) d 8.04 (2H, d, J = 7.9 Hz), 7.58-7.53 (1H, m), 
7.44 (2H, d, J = 7.22 Hz), 6.22 (1H, d, J = 11.0 Hz), 5.81 (1H, d, J =11.0 Hz), 4.96-4.85 (1H, m), 
3.75-3.65 (1H, m), 3.13 (1H, dd, J = 4.1, 12.6 Hz), 2.80 (1H, dd, J = 3.1, 11.5 Hz), 2.48-2.36 (2H, 
m), 2.14 (1H, t, J  = 11.4 Hz), 2.03-1.87 (5H, m), 1.75-1.47 (10H, m), 1.29 (9H, s), 0.93 (3H, d, J 
= 6.2 Hz), 0.88 (9H, s), 0.57 (3H, s), 0.08 (6H, d, J = 6.2 Hz); 13C NMR (75 MHz, CDCl3) d 
165.98, 143.15, 133.01, 130.60, 129.71 (t, 1JCF = 249.3 Hz), 129.45, 122.99, 115.66, 76.07 (t, 2JCF 
= 28.2 Hz), 70.44, 68.72, 56.48, 56.39, 46.44, 45.90, 41.83, 40.58, 35.94, 33.71, 28.94, 27.32 (t, 
2JCF = 22.4 Hz), 25.93, 24.57, 23.57, 22.36, 18.71, 18.21, 12.81, 2.45, -4.48,-4.55. HRMS ESI: 
m/z calcd for C42H68F2Na1O4Si2: 753.4521 [M+ Na]+, found 753.4528.  
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 (1R,3S,E)-5-(2-((1R,7aR,E)-1-((R)-5,5-Difluoro-6-hydroxy-6-methylheptan-2-yl)-7a-
methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol (6a): 
 
 
 
 
To a solution of 39a (15 mg, 20 µmol) in MeOH (0.4 mL) and THF (1.6 mL) was added K2CO3 
(4.2 mg, 36 µmol) at room temperature under argon, and the mixture was stirred overnight. To the 
reaction mixture was added saturated NH4Cl, and aqueous layer was extracted with ethyl acetate 
for three times. The combined organic layer was washed with water and brine, dried over MgSO4, 
filtered and concentrated in vacuo.  The residue was purified by silica gel column (12% ethyl 
acetate-hexanes) to give alcohol, which was then dissolved in THF (1 mL), and HF·Py (0.14 mL) 
was added, and the resulting mixture was stirred for 24 h at room temperature. To the reaction 
mixture was added saturated Na2S2O3, and aqueous layer was extracted with ethyl acetate for three 
times. The extracts were washed with water and brine, dried over MgSO4, filtered and concentrated 
in vacuo. The residue was first eluted using 3% MeOH-CH2Cl2 on a silica gel column, and then 
again purified on a preparative TLC plate using 5% MeOH-CH2Cl2 as the mobile phase to give 6a 
(5.7 mg, 64%). Spectral data for 6a: 1H NMR (300 MHz, CDCl3) d 6.34 (1H, d, J = 11.0 Hz), 5.86 
(1H, d, J = 11.0 Hz), 4.02 (2H, br), 2.82 (1H, dd, J = 4.1, 10.3 Hz), 2.57 (1H, dd, J = 5.8, 15.3 Hz), 
2.51-2.43 (2H, m), 2.33-2.18 (3H, m), 2.08-1.65 (13H, m), 1.31 (9H, s), 1.24 (3H, t, J = 7.2 Hz), 
0.94 (3H, d, J = 6.2 Hz), 0.55 (3H, s); 13C NMR (75 MHz, CDCl3) d 142.70, 130.15, 126.44 (t, 
1JCF = 249.8 Hz), 124.12, 115.52, 73.48 (t, 2JCF = 27.4 Hz), 68.96, 68.78, 56.34, 56.19,45.83, 
45.12, 40.51, 40.29, 36.75, 35.80, 29.79, 28.98, 27.40 (t, 2JCF = 24.5 Hz), 26.87, 23.67, 22.33, 
18.74, 12.18.  HRMS ESI: m/z calcd for C26H42F2Na1O3: 463.2999 [M+ Na]+, found  463.3048. 
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 (1R,3S,Z)-5-(2-((1R,7aR,E)-1-((R)-5,5-difluoro-6-hydroxy-6-methylheptan-2-yl)-7a-
methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol (6b):  
 
 
 
 
Similar to 39a, to a solution of 39b (16 mg, 20 µmol) in MeOH (0.4 mL) and THF (1.6 mL) was 
added K2CO3 (4.3 mg, 36 µmol) at room temperature under argon, and the mixture was stirred 
overnight. To the reaction mixture was added saturated NH4Cl, and aqueous layer was extracted 
with ethyl acetate for three times. The combined organic layer was washed with water and brine, 
dried over MgSO4, filtered and concentrated in vacuo.  The residue was purified by silica gel 
column (12% ethyl acetate-hexanes) to give alcohol, which was then dissolved in THF (1 mL), 
and HF·Py (0.15 mL) was added, and the resulting mixture was stirred for 24 h at room 
temperature. To the reaction mixture was added saturated Na2S2O3, and aqueous layer was 
extracted with ethyl acetate for three times. The extracts were washed with water and brine, dried 
over MgSO4, filtered and concentrated in vacuo. The residue was first eluted using 3% MeOH-
CH2Cl2 on a silica gel column, and then again purified on a preparative TLC plate using 5% 
MeOH-CH2Cl2 as the mobile phase to give 6b (6.1 mg, 64%). Spectral data for 6b: 1H NMR (300 
MHz, CDCl3) d 6.32 (1H, d, J = 11.0 Hz), 5.85 (1H, d, J = 11.0 Hz), 3.91 (2H, m), 2.81 (1H, dd, 
J = 3.8, 12.0 Hz), 2.58 (1H, dd, J = 3.8, 13.6 Hz), 2.51-2.37 (3H, m), 2.28-2.22 (1H, q, J = 6.8 H), 
2.09-1.97 (10H, m), 1.84-1.64 (8H, m), 1.30 (9H, s), 1.24 (3H, t, J = 7.2 Hz), 0.94 (3H, d, J = 6.2 
Hz), 0.55 (3H, s); 13C NMR (75 MHz, CDCl3) d  142.73, 130.26, 125.57 (t, 1JCF = 251.4 Hz), 
123.84, 115.56, 73.67 (t, 2JCF = 27.4 Hz), 68.95, 68.67, 56.35, 56.25, 45.85, 45.19, 41.17, 40.54, 
36.91, 35.81, 29.79, 28.95, 27.61 (t, 2JCF = 24.5 Hz, 16.87, 23.67, 23.54, 22.53, 18.73, 12.18.  
HRMS ESI: m/z calcd for C26H42F2Na1O3: 463.2999 [M+ Na]+, found 463.2970. 
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Proton NMR of Compound 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon NMR of Compound 10 
	 72	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proton NMR of Compound 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbon NMR of Compound 7 
	 73	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proton NMR of Compound 21 
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Proton NMR of Compound 23 
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